[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_101":102},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":31,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":-5,"_48":49,"_50":-5,"_51":-5,"_52":53,"_54":55,"_56":57,"_58":42,"_59":42,"_60":61,"_62":42,"_63":64},"id","fd8r8afpu4faiu3gixovhmyuw","revision",2,"title","Amesite Inc. 将召开年度股东大会，拟进行反向拆股并授权私募融资","originalTitle","Amesite Inc. (0001807166) (Filer)","summary","Amesite Inc. 将于2026年12月10日召开年度股东大会，拟进行1-for-2至1-for-250的反向拆股，并授权在一年内以低于纳斯达克最低价格发行证券，募资总额最高可达2500万美元。公司已发行并流通的普通股为6,549,851股，会议法定人数需由33 1/3%的流通股出席。","reason","Amesite Inc. 将在2026年12月10日召开年度股东大会，拟进行反向拆股并授权私募融资最高2500万美元，可能影响股东权益。","source",{"_12":92,"_93":94,"_9":95,"_96":42,"_97":98,"_99":100},"links",{"_89":90,"_77":91},"publishedAt","2026-10-14T20:10:30.000Z","discoveredAt","2026-10-14T22:53:30.681Z","timelineAt","category","tip","tags",[83,84,85,86,87,88],"stockSymbols",[82],"score",60,"selected",true,"channel","news","story",{"_72":73,"_16":74},"x","readingMode","full","author","language","body",{"_64":76,"_77":-5,"_78":79,"_80":81},"outline",[],"relatedStories",[75],"indexable","markdownAvailable","group",{"_65":66,"_45":67,"_68":15,"_69":70,"_71":70},"hasTranslation","bodyLanguage","zh","factId","fg7DV6LP6xiY",{"_72":73,"_16":74},"reportCount","additionalSourceCount",0,"developmentCount","publicId","b2452e7d-a531-4a1d-af46-833eea0c3788","Amesite Inc. 2026年度股东大会筹备",{"_72":73,"_16":74},"

美国

证券交易委员会

华盛顿特区 20549

14A 表信息

根据《1934 年证券交易法》第 14(a) 条的代理声明

(第__次修订)

由注册人提交 ☒

由注册人以外的方提交 ☐

选择适用的框：

\n\n\n\n\n\n\n\n\n\n\n

☐	初步代理声明
\n	\n
☐	保密文件，仅限委员会使用（根据规则 14a-6(e)(2) 允许）
\n	\n
☒	最终代理声明
\n	\n
☐	最终附加材料
\n	\n
☐	根据 §240.14a-12 招募材料

Amesite Inc.

(注册人根据其章程指定的名称)

(如果提交代理声明的人员不是注册人，请填写姓名)

支付文件费用（勾选所有适用的框）：

\n\n\n\n\n\n\n

☒	无需支付费用
\n	\n
☐	已先前支付初步材料的费用
\n	\n
☐	根据《证券交易法》规则 14a-6(i)(1) 和 0-11 第 25(b) 项要求的表格计算的费用。

AMESITE INC.

607 Shelby Street, Suite 700 PMB 214

密歇根州底特律市 48226

2026 年 10 月 14 日

股东年度会议通知

将于 2026 年 12 月 10 日举行

尊敬的股东：

我们很高兴邀请您参加 Amesite Inc.（“公司”）的年度股东会议（“年度会议”），该会议将于 2026 年 12 月 10 日美国东部时间上午 10:00 举行。年度会议将在 www.virtualshareholdermeeting.com/AMST2027 虚拟举行。

除了在年度会议前提交代理投票外，您还可以在年度会议期间通过电子方式投票。有关虚拟会议的更多细节包含在随附的代理声明中。在年度会议上，我们已发行的普通股的持有者将就以下事项进行表决：

\n\n

选举两名第三届董事，任期为三年或直至其继任人被适当选举并就职；

\n\n\n\n

批准任命 Novogradac & Company LLP 为公司截至 2027 年 6 月 30 日财年的独立注册公共会计事务所；

\n\n\n\n

批准对公司章程的修订，根据董事会的决定，对公司已发行和流通的普通股进行反向股票分割，比例为 1:2 至 1:250，具体比例由董事会决定，并在批准之日起一年内完成反向股票分割；

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

	4.	根据纳斯达克上市规则 5635(d)，批准在一次或多次非公开发行中发行证券，此类发行超过流通股的 19.99%，且价格低于纳斯达克最低价格，在批准之日起一年内，受某些限制，总收益不超过 2500 万美元；以及

	5.	就公司指定高管的薪酬进行咨询性批准；

	6.	就公司指定高管的薪酬未来咨询性投票的首选频率表达意见；以及

\n\n

处理年度会议及任何延期或推迟期间可能提出的其他事项。

我们的董事会已确定2026年10月13日为记录日期（“记录日期”），以确定有权获得年度会议通知并参与投票的股东。

我们正在根据美国证券交易委员会的“通知与访问”规则，通过互联网向某些股东分发代理材料。我们认为这种方法可以使股东及时且方便地接收代理材料并进行投票，同时降低交付成本并减少年度会议对环境的影响。我们将于2026年10月14日左右开始向股东邮寄《互联网代理材料可用性通知》（“互联网可用性通知”），而不是邮寄代理声明、代理投票卡以及截至2026年6月30日财年结束的10-K表格年度报告。互联网可用性通知中包含如何访问代理材料、投票以及如需可获取代理材料纸质副本的说明。

如果您计划参加：

要参加此次虚拟举行的年度会议，您必须准备好您的控制号码，并按照您的代理投票卡或投票指示表上的说明进行操作。您可以在年度会议期间通过会议网站上的说明进行投票。请在年度会议开始前留出足够的时间完成在线签到流程。作为年度会议期间投票的替代方式，您可以根据要求邮寄纸质代理声明和其他代理材料的股东，通过邮寄的代理投票卡进行投票。如果您的股份以经纪商、信托、银行或其他代理人名义持有，并且您通过您的经纪商或其他中介收到这些材料，请按照此类经纪商或其他中介提供的说明完成并返回材料，或直接联系您的经纪商，以获取由您的代理人持有人发出的授权您参加年度会议并在此期间投票的代理书。未能这样做可能导致您的股份在年度会议期间无法通过代理进行投票。您的投票非常重要。

\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	根据董事会命令

\n
2026年10月14日	/s/ Ann Marie Sastry, Ph.D.
\n	\n Ann Marie Sastry, Ph.D. \n 董事会主席

无论您是否计划参加虚拟年度会议，我们敦促您尽快投票。这将确保年度会议有法定人数。及时投票将节省公司额外征集的费用和额外工作。现在提交您的代理书不会妨碍您在希望的情况下在年度会议期间投票，因为您的代理书可根据您的选择撤销。您的投票非常重要，请今天采取行动！

关于2026年12月10日举行的股东会议代理材料可用性的注意事项：

我们的股东年度会议正式通知、代理声明、代理投票卡格式和

2026年股东年度报告可在以下网址获取：

www.proxyvote.com

AMESITE INC.

607 Shelby Street, Suite 700 PMB 214

密歇根州底特律市 48226

关于年度股东大会的委托书声明

年度股东大会

将于 2026 年 12 月 10 日举行

Amesite Inc.（“Amesite”或“公司”）的董事会正在征求您的委托书，以便在将于 2026 年 12 月 10 日举行的年度股东大会（“年度股东大会”）上投票，会议将于东部时间上午 10:00 以虚拟形式在线举行，通过访问 www.virtualshareholdermeeting.com/AMST2027 参加，以及任何延期会议。

本委托书声明包含有关年度股东大会的信息。今年的股东年度大会将以虚拟会议形式举行。参加虚拟会议的股东将享有与参加现场会议相同的权利和参与机会。您可以通过访问 www.virtualshareholdermeeting.com/AMST2027 在线参加并参与年度股东大会的实时网络广播。除了在年度股东大会之前提交委托书进行投票外，您还可以在年度股东大会期间通过电子方式投票。

互联网上可获取委托书材料、委托书声明和委托书表格的通知，将于 2026 年 10 月 14 日左右向所有有权在年度股东大会上投票的股东分发并提供在线访问。只有在 2026 年 10 月 13 日拥有我们普通股的股东才有权在年度股东大会上投票。

AMESITE INC.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	页码
关于本委托书声明和投票的一般信息	1
提案 1：选举董事	8
提案 2：批准任命独立注册公共会计事务所	19
提案 3：股票反向拆分	21
提案 4：授权在非公开发行中发行证券	23
提案 5：对高管薪酬的咨询性投票批准	24
提案 6：对未来高管薪酬咨询性投票频率的咨询性投票	25
审计委员会报告	26
高管人员	27
高管薪酬	28
股权激励计划信息	32
特定受益所有人和管理层的股票所有权	33
特定关系和关联方交易	34
其他事项	35
2027 年度股东大会的股东提案	35
股东对董事会成员提名的建议	36
分发	37
年度报告	37
附录 A - 公司章程修正案	A-1

关于本委托书声明和投票的一般信息

什么是委托书？

代理是指法律指定的另一个人代为投票您所拥有的股票。那个人被称为代理。如果您在书面文件中指定某人为您的代理，该文件也被称为代理文件或代理卡。通过填写、签署并返回随附的代理卡，您是在指定安·玛丽·萨斯特里博士（Ann Marie Sastry, Ph.D.），公司的首席执行官，作为您在年度会议上的代理，并授权该代理按照您在代理卡上指示的方式在年度会议上投票。这样，无论您是否参加年度会议，您的股票都将被投票。即使您计划参加年度会议，我们仍建议您按照以下描述的方式之一进行投票，这样即使您无法参加或决定不参加年度会议，您的投票也将被计算在内。

什么是代理文件？

代理文件是根据美国证券交易委员会（“SEC”）的法规，当我们要求您签署代理卡，指定萨斯特里博士作为您的代理代为投票时，我们必须提供给您的文件。

为什么我会收到《互联网可用代理材料通知》而不是纸质代理材料副本？

我们正在使用SEC的“通知与访问”模式（“Notice and Access”），这使我们能够通过互联网作为主要方式提供代理材料。我们认为，“通知与访问”为股东提供了方便的访问代理材料和投票的方式，同时使我们能够节约自然资源并减少印刷和分发代理材料的成本。\n在2026年10月14日左右，我们开始向股东邮寄《互联网可用代理材料通知》，其中包含如何通过互联网访问我们的代理材料以及如何在线投票的说明。《互联网可用代理材料通知》不是代理卡，不能用于投票。如果您今年收到了《互联网可用代理材料通知》，除非您按照《互联网可用代理材料通知》上的说明请求材料，否则您将不会收到代理材料的纸质副本。

如果我收到多套代理材料意味着什么？

如果您收到多套代理材料，您的股票可能以多个名称或不同账户的形式登记。请填写、签署并返回每张代理卡，以确保您所有的股票都被投票。

我如何参加年度会议？

年度会议将于2026年12月10日上午10点（东部时间）以虚拟形式在线举行，您可以通过访问www.virtualshareholdermeeting.com/AMST2027参加。

谁有资格投票？

董事会已确定2026年10月13日营业结束时为确定有权获得年度会议通知并投票的股东的记录日期（“记录日期”）。在记录日期，共有6,549,851股流通普通股。每一股普通股代表一票，可在年度会议可能提出的每个提案上投票。

以记录持有人身份持有股票和以受益所有人（以“街头名称”持有股票）身份持有股票有什么区别？

如果您持有的股份以您的姓名在我们的股份过户代理机构Continental Stock Transfer & Trust Company注册，您就是这些股份的“记录持有者”。如果您是记录持有者，这些委托书材料已由公司直接提供给您。

如果您持有的股份存放在股票经纪账户、银行或其他记录持有者处，您将被视为这些以“街头名称”持有的股份的“实际受益人”。如果您的股份以街头名称持有，这些委托书材料已由该机构转发给您。持有您账户的机构被视为年度会议投票的记录股东。作为实际受益人，您有权指示该机构如何投票您的股份。有关在未提供具体指示时如何投票的信息，请参阅下方“如果我没有提供具体指示，我的股份将如何投票？”。

谁可以参加年度会议？

只有我们普通股的记录持有者和实际受益人，或其合法授权的代理人，才可以参加年度会议。如果您持有的普通股以街头名称持有，您需要提供一份经纪报告副本或其他反映您在记录日期的股票所有权的文件。

我要投票什么？

有六项事项安排投票：

\n\n

选举两名第三类董事，任期为三年或直至继任人被合法选举并就职；

\n\n

批准任命Novogradac & Company LLP为公司2027年6月30日结束的财年的独立注册公共会计事务所；

\n\n

批准对公司章程的修订，由董事会自行决定，以对公司已发行和流通的普通股进行反向股票分割，比例为1比2至1比250，具体比例由董事会自行决定，并在批准后一年内完成反向股票分割；

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

	4.	为符合纳斯达克上市规则5635(d)的目的，批准在一次或多次非公开发行中发行证券，此类发行超过流通股的19.99%，且价格低于纳斯达克最低价格，在批准后一年内，受某些限制，总收益不超过2500万美元；
	\n
	5.	批准对公司指定高管的薪酬进行咨询性投票；以及
	\n
	6.	咨询性地表明未来对公司指定高管薪酬进行咨询性投票的首选频率。

如果在年度会议上提出了其他事项怎么办？

董事会目前没有其他事项将在年度会议上提交审议。如果在年度会议上提出了其他事项，随附委托书中的指定人员将根据其最佳判断对这些事项进行投票。

我如何投票？

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

邮寄	互联网	电话	在会议现场在线投票
邮寄您的签名委托书或投票指示卡。	在会议前通过互联网：	拨打：	您可以在会议期间进行投票：
	www.proxyvote.com	1-800-690-6903	www.virtualshareholdermeeting.com/AMST2027

在册股东

如果您是登记在册的股东，您可以按照上述说明通过邮寄、电话或在线方式投票。您也可以通过邮寄方式提交您的委托书，方法是按照随附在您的委托书卡上的说明操作。通过互联网提交委托书的截止时间是2026年12月9日东部时间晚上11:59。我们董事会指定的委托人Ann Marie Sastry，博士，将根据您的指示投票。如果您参加年度会议的实时网络广播，您还可以在年度会议期间直到投票结束前通过电子方式投票。

以经纪人名义持有股份的受益所有人

如果您是经纪人名义持有人，您的经纪人或代理人公司是股份的法定登记所有者，它可能会向您提供与年度会议相关的材料。请按照您收到的材料上的说明访问我们的委托书材料并投票，或请求我们委托书材料的纸质或电子邮件副本。这些材料包括一张投票指示卡，以便您可以指示您的经纪人或代理人如何投票。请查看投票指示卡或联系您的经纪人或其他代理人，以确定您是否可以在会议前通过互联网提交您的投票指示，以及如果您参加年度会议的实时网络广播，您是否可以在会议期间直到投票结束前通过电子方式投票。

所有有权投票并在年度会议前收到并正确填写和执行的委托书（未被撤回）将在年度会议上按照在年度会议前提交的委托书中的指示进行投票。我们提供互联网委托投票，以便您可以通过在线方式投票，其程序旨在确保您的委托投票指示的真实性和正确性。然而，请注意，您必须承担与您的互联网接入相关的任何费用，例如互联网接入服务提供商和电话公司的使用费用。

我有多少投票权？

在每个需要投票的事项上，您在在册日期收盘时拥有的每一股普通股都有一票。

我的投票是否保密？

是的，您的投票是保密的。只有选举监督员、协助处理和计票的人员以及因法律原因需要访问的人员才能看到您的投票。除法律要求外，此信息不会被披露。

什么是法定人数？

在年度会议上进行业务，我们必须有法定人数。当截至记录日有权投票的股份的三分之一（33 1/3%）出席或通过代理出席时，即构成法定人数。因此，为了在年度会议上达到法定人数，必须有2,183,284股出席或通过代理出席。只有在您提交有效的委托书（或由您的经纪人、银行或其他代理人代为提交）或在年度会议上进行投票时，您的股份才会被计入法定人数。弃权和经纪人不投票将计入法定人数要求。公司拥有的股份不被视为流通股，也不被视为在年度会议上出席。如果年度会议上没有法定人数，年度会议的主席或有权在年度会议上投票的股东可根据适用法律的规定将年度会议推迟到未来日期。

如果我没有具体指示，我的股份将如何被投票？

我们必须按照您的指示投票。如果记录在册的股东对某项事项没有具体指示，但已授权我们一般性地投票，则将按以下方式投票：

\n\n

“赞成”选举两名第三届董事，任期为三年或直至其继任人被适当选举并就职；

\n\n

“赞成”批准任命Novogradac & Company LLP为公司2027年6月30日止财年的独立注册公共会计事务所；

\n\n

“赞成”批准对公司章程的修订，根据董事会的裁量权，对已发行和流通的普通股进行反向股票分割，比例为1比2至1比250；

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	4.	“赞成”根据纳斯达克上市规则5635(d)的规定，批准在一次或多次非公开发行中发行证券，此类发行在批准之日起一年内超过流通股的19.99%，且价格低于纳斯达克最低价格，受某些限制，总收益不超过2500万美元；

\n	\n
\n	5.	“赞成”对公司的高级管理人员薪酬进行咨询性批准；以及

\n	\n
\n	6.	“1年”作为未来对公司高级管理人员薪酬进行咨询性投票的首选频率。

这种授权将存在，例如，如果记录在册的股东仅签署、注明日期并返回委托书卡，但未就一项或多项提案指示如何投票。如果其他事项在年度会议上适当提出，而您未提供具体的投票指示，您的股份将由安妮·玛丽·萨斯特里博士（Ann Marie Sastry, Ph.D.）根据董事会指定的代理人的裁量进行投票。

如果您的股份以“街头名称”持有，请参阅下方“什么是经纪人不投票？”部分，了解银行、经纪人和其他此类记录在册持有人根据其客户或其他受益人的意愿自行投票的权限。

投票如何计算？

投票将由为年度会议指定的选举监督员进行统计，该监督员将分别统计董事选举的“赞成”、“撤回”和经纪人非投票；对于其他提案，统计“赞成”和“反对”投票、弃权和经纪人非投票。弃权和经纪人非投票将不计入任何提案的投票结果统计中，因此对这些提案没有影响。

什么是经纪人非投票？

“经纪人非投票”是指经纪人持有的以“街头名称”为受益人持有的股份，由于以下原因未就一项提案进行投票：(1) 经纪人未收到受益人股东的投票指示，以及(2) 经纪人无权自行决定投票这些股份。

我们的普通股在纳斯达克资本市场上市。然而，根据目前适用于经纪人非投票的纽约证券交易所（“NYSE”）规则和解释：(i) 第1项关于董事选举的提案被视为非自由裁量事项，经纪人无权自行决定投票未收到指示的股份；(ii) 第2项关于批准任命Novogradac & Company LLP为我们独立注册公共会计事务所的提案被视为自由裁量事项，经纪人将被允许自行决定投票未收到指示的股份；(iii) 第3项关于批准反向股票分割的提案被视为非自由裁量事项，经纪人将不允许自行决定投票未收到指示的股份；(iv) 第4项关于批准非公开发行证券的提案被视为非自由裁量事项，经纪人将不允许自行决定投票未收到指示的股份；(v) 第5项关于批准我们指定高管薪酬的咨询投票的提案被视为非自由裁量事项，经纪人将不允许自行决定投票未收到指示的股份；以及(vi) 第6项关于未来高管薪酬咨询投票频率的咨询投票的提案被视为非自由裁量事项，经纪人将不允许自行决定投票未收到指示的股份。由于NYSE规则适用于所有NYSE会员经纪人，因此即使我们的普通股在纳斯达克资本市场上市，此禁令也适用于年度会议。

我们预计持有您股份的机构将拥有自由裁量投票权，即使该机构未收到您的投票指示，也可以就被视为“常规”事项的提案投票。然而，某些机构可能选择在未收到受益人指示的情况下不投票，即使它们拥有自由裁量权。我们预计第2项提案将被视为“常规”事项。

另一方面，如果您未向持有您股份的机构提供投票指示，我们预计这些股份将不会就被视为“非常规”事项的提案进行投票，因为持有您股份的机构通常在非常规事项上没有自由裁量权来投票未收到指示的股份。我们预计第1、3、4、5和6项提案将被视为“非常规”事项。

组织可能就其在特定提案上投票的能力得出与本委托书所表达的预期不同的结论。\n因此，我们建议您就所有提案向持有您股份的组织提供投票指示，以确保\n您的投票被计算。我们预计组织将按照您的指示投票。

什么是弃权？

弃权是股东对某项提案选择不投票的明确决定。根据特拉华州法律，弃权被视为在年度股东大会上具有投票权的股份。\n通常，除非适用法律另有规定，我们的公司章程（“公司章程”）规定，股东的行动（除选举董事外）只要多数投票赞成该行动即视为通过。\n因此，弃权对提案1、提案2、提案3、提案4、提案5或提案6没有影响。

批准每项提案需要多少票？

下表总结了将进行投票的提案、批准每项提案所需的投票以及投票的计算方式：

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

提案

所需投票

投票
\n选项

“保留”
\n或
\n“弃权”
\n投票的
\n影响

经纪人
\n自由裁量
\n投票
\n是否允许

提案编号1：

董事选举

投票中多数票。这意味着获得最高数量的“赞成”票的候选人将被选为董事。

“赞成”

“保留”

“全部赞成除外”

无⁽¹⁾

无⁽³⁾

提案编号2：批准任命独立注册公共会计事务所

有权就该事项投票的股东投票中多数票赞成。

“赞成”

“反对”

“弃权”

无⁽²⁾

是⁽⁴⁾

提案编号3：

反向股票分割

有权就该事项投票的股东投票中多数票赞成。

“赞成”

“反对”

“弃权”

无⁽²⁾

无⁽³⁾

提案编号4：

授权发行非公开发行证券

有权就该事项投票的股东投票中多数票赞成。

“赞成”

“反对”

“弃权”

无⁽²⁾

无⁽³⁾

提案编号5：

批准高管薪酬的咨询投票（“说-对-薪酬”）

有权就该事项投票的股东投票中多数票赞成。

“赞成”

“反对”

“弃权”

无⁽²⁾

无⁽³⁾

提案编号6：

未来“说-对-薪酬”投票频率的咨询投票

获得最多投票的频率选项（一年、两年或三年）将被视为股东的首选频率。

“1年”

“2年”

“3年”

“弃权”

无⁽⁵⁾

无⁽³⁾

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

(1)	“保留”投票的效果与弃权相同，因为董事是通过多数投票选举的。

\n
(2)	标记为“弃权”的投票不被视为已投出的投票，因此不会影响该提案的结果。

\n
(3)	由于该提案不被视为自由裁量事项，经纪人无权自行决定对未收到指示的股份进行投票。

\n
(4)	由于该提案被视为自由裁量事项，经纪人被允许自行决定对未收到指示的股份进行投票。然而，某些机构可能选择在未收到实际受益人指示的情况下不投票，即使他们拥有自由裁决权。机构可能就其对特定提案投票的能力得出与本委托书中的预期不同的结论。因此，我们鼓励您就所有提案向持有您股份的机构提供投票指示，以确保您的投票被计算在内。我们预计机构将按照您的指示对股份进行投票。

\n
(5)	标记为“弃权”的投票不适用于三个频率选项中的任何一个，因此不会影响确定哪个频率获得最多投票数。

投票程序是怎样的？

在就董事选举进行委托投票时，您可以对所有候选人投赞成票，对所有候选人投弃权票，或者对特定候选人投弃权票。对于其他提案，您可以投赞成票或反对票，或者可以选择对提案弃权。您应在附带的委托书或投票指示表上明确说明您的选择。

我的委托书可以撤销吗？

您可以在委托书被投票之前随时撤销您的委托书并重新获得投票权，方法是向公司秘书提交书面通知，通过递交一份填写完整、日期较晚的委托书或投票指示表，或在年度会议上进行投票。所有关于撤销委托书的书面通知及其他相关通信应寄往：Amesite Inc., 607 Shelby Street, Suite 700 PMB 214, Detroit, Michigan 48226，收件人：秘书。您最新版的委托书或互联网委托书将被计算在内。

谁来支付准备和邮寄委托书材料的费用？

准备、整理和邮寄这些委托书材料的所有费用以及所有代理委托的费用将由我们支付。除了通过邮寄进行的征集外，我们的高管和其他员工还可以通过电话或亲自进行代理委托的征集。这些人除正常工资外不会获得其他报酬。还将与经纪公司和其他托管人、代理人和受托人安排，将征集材料转发给由这些人持有的股份的实际受益人，我们可能会报销他们因转发征集材料而产生的合理差旅费用。

我有异议股东的评估权吗？

根据特拉华州法律或Amesite的章程文件，股东在年度会议上将要投票的事项上不享有评估权。

我如何得知年度会议投票的结果？

初步投票结果将在年度会议上公布。此外，最终投票结果将在我们预计于年度会议后四个工作日内向美国证券交易委员会（SEC）提交的8-K表格的当前报告中披露。如果我们在年度会议后四个工作日内无法及时获得最终投票结果以向SEC提交8-K表格，我们打算提交一份8-K表格以公布初步结果，并在我们得知最终投票结果后的四个工作日内提交修订版的8-K表格以公布最终结果。

提案1：

董事选举

董事会规模和结构

我们的公司章程（“公司章程”）和公司章程规定，我们的业务将在董事会的指导下进行管理。我们的董事会必须由至少一名董事组成。

我们的董事会目前由五名董事组成。我们的公司章程规定，我们董事会的董事人数应由董事会通过的决议单独确定。董事将被划分为三个类别，分别称为第一类、第二类和第三类，尽可能人数相等。董事将根据董事会通过的决议或决议分配到每个类别中。在即将召开的股东年度会议上，第三类董事的任期将届满，并将选举第三类董事担任为期三年的完整任期。在下一次股东年度会议上，第一类董事的任期将届满，并将选举第一类董事担任为期三年的完整任期。在随后的股东年度会议上，第二类董事的任期将届满，并将选举第二类董事担任为期三年的完整任期。在每次后续的股东年度会议上，将选举董事担任为期三年的完整任期，以接替在该年度会议期间任期届满的类别董事。每位董事将任职至其继任者被适当选举和确认，或直至其提前死亡、辞职或被罢免。董事会成员人数的减少不会缩短任何现任董事的任期。我们的董事会在截至2026年6月30日的财年中召开了四次会议。在截至2026年6月30日的财年中，我们董事会的所有成员至少出席了75%的董事会和相关委员会会议。作为一项政策，我们鼓励董事参加股东会议，但不要求必须出席。我们目前的四位董事参加了去年的股东年度会议。

在考虑董事是否具备整体上的经验、资格、特质或技能，以使我们的董事会能够在我们的业务和结构背景下有效地履行监督职责时，董事会主要关注每位董事的背景和经验，这些信息反映在下面每位董事的个人传记中。我们认为，我们的董事提供了与我们业务规模和性质相关的适当的经验和技能组合。

除非《特拉华州普通公司法》（DGCL）另有规定，根据我们的公司章程和细则，董事会或任何个别董事只能在股东会议上以全体股东的赞成票（该票数至少占公司所有具有投票权的股份的六十六又三分之二百分比（66 2/3%））投票通过后，因正当理由被免职，该会议专门为此目的而召开。

选举候选人

Gilbert\nS. Omenn，M.D., Ph.D. 和 George Parmer 已由董事会提名为在年度会议上再次参选。\n如果在年度会议上由股东选举通过，Gilbert S. Omenn，M.D., Ph.D. 和 George Parmer 将从年度会议之日起开始担任为期三年的完整任期，直至其继任者被选举和就职，或直至其提前死亡、辞职或被免职。\n

每位被提名为选举的人员已同意在当选后任职，管理层没有理由认为任何候选人无法任职。然而，如果在年度会议之前，董事会得知任何候选人因任何原因无法任职，原本应投给该候选人的委托书将被投给董事会选定的替代候选人。\n或者，根据董事会的酌情决定，委托书可以投给因任何候选人无法任职而减少数量的候选人。\n董事会没有理由认为任何候选人无法任职。

董事会候选人的信息

以下页面包含有关董事候选人的某些个人资料信息，包括目前担任的所有职位、过去五年的主要职业和业务经验，以及该候选人目前担任董事或在过去五年内曾担任董事的其他公开上市公司的名称。

Gilbert\nS. Omenn，M.D., Ph.D. - 董事

欧门博士（85岁）自2020年3月起一直是我们董事会的成员。在被任命为董事会成员之前，欧门博士曾是我们董事会的顾问。欧门博士是密歇根大学计算医学与生物信息学、内科学、人类遗传学和公共卫生领域的哈罗德·T·夏皮罗杰出大学教授。欧门博士拥有数十年的上市公司董事会经验，包括在安进公司（纳斯达克股票代码：AMGN）任职27年，以及在罗姆&哈斯公司任职22年。他曾是华盛顿大学公共卫生与社区医学学院院长（1982-1997），随后担任密歇根大学医学事务执行副总裁和密歇根大学医疗系统首席执行官（1997-2002）。此外，他还曾是原子能委员会的白宫学者（1973-1974），白宫科技政策办公室和管理与预算办公室的副主任（1977-1981），AAAS“2061项目：面向所有美国人的科学”咨询委员会成员（1986-1996），总统/国会风险评估与风险管理委员会主席（1994-1997），美国科学促进会（AAAS，2006年）主席，国家卫生研究院科学管理评审委员会成员（2012-2014），国家医学科学院（NAM，2015-2017）理事会成员，目前是国家科学院政策与全球事务委员会的成员。他还是Angion Biomedica和Galectin Therapeutics的董事。我们认为，欧门博士在上市公司、学术界、科学教育和医疗保健方面的经验使他有资格担任我们的董事会成员。

乔治·帕默 - 董事

乔治·帕默（87岁）自2020年11月起一直是我们董事会的成员。乔治是Linkbancorp, Inc.的董事会成员，曾是宾夕法尼亚州梅赛德斯大学的董事会主席。他是住宅房屋建筑和开发公司Fine Line Homes的创始人兼总裁，该公司在从纽约到北卡罗来纳州的东海岸地区有开发项目。他还是全国性公司Residential Warranty Corporation的创始人兼总裁，以及位于科罗拉多州、宾夕法尼亚州和德克萨斯州的三家保险公司的创始人兼总裁。我们认为，帕默先生的商业和领导经验使他有资格担任我们的董事会成员。

关于目前未参加选举的董事会成员的信息

以下页面包含某些关于目前未参加选举的董事会成员的传记信息，包括目前担任的所有职位、过去五年的主要职业和业务经历，以及该董事目前或在过去五年内曾担任董事的其他上市公司名称。

J. 迈克尔·洛什 - 董事

洛什先生（80岁）自2018年2月起一直是我们董事会的成员。洛什先生曾在卡迪纳尔健康公司（Cardinal Health）担任首席财务官，任期从2004年7月至2005年5月。洛什先生曾在通用汽车公司（General Motors）工作，时间从1964年至2000年。他曾在1994年7月至2000年8月期间担任通用汽车公司的首席财务官和执行副总裁。他是Aon PLC（纽约证券交易所代码：AON）的董事（2003年至今），也是卡迪纳尔健康公司（纽约证券交易所代码：CAH）的董事（1996年至2009年以及2018年至2021年）。洛什先生曾担任AMB公司、Care Fusion公司、电子数据系统公司、德尔福汽车系统公司、休斯电子公司、桂格燕麦公司、TRW汽车公司、HB Fuller公司和普洛斯公司（Prologis, Inc.）的董事。他曾担任GMAC、Metaldyne公司和Masco公司（纽约证券交易所代码：MAS）董事会主席。洛什先生拥有凯特灵大学（Kettering University）机械工程学士学位和哈佛大学（Harvard University）工商管理硕士学位。我们认为，洛什先生在上市公司方面的经验使他有资格担任我们董事会的董事。

安·玛丽·萨斯特里博士 - 首席执行官、总裁、董事会主席

萨斯特里博士（59岁）自2017年11月公司成立起一直担任我们的首席执行官、总裁和董事会主席。从2008年4月至2015年10月，萨斯特里博士担任Sakti3公司的总裁、首席执行官、董事会成员和联合创始人，该公司被《麻省理工科技评论》评为2015年全球50家最聪明的公司之一。由全球风险投资团队支持的Sakti3公司在2015年以9000万美元的价格出售给戴森有限公司（Dyson Ltd.）。2015年，萨斯特里博士受邀前往白宫，因其技术创新而受到表彰，并与巴拉克·奥巴马总统会面。从2015年10月至2017年11月，萨斯特里博士继续在戴森公司担任全球固态电池团队负责人，专注于技术战略和进步、员工和组织发展以及合作伙伴关系的建立。她的技术和商业工作被《华尔街日报》、《财富》、《福布斯》、《经济学人》、《今日美国》、《纽约时报》以及《Inc.》杂志的封面报道。

在创办自己的公司之前，\n萨斯特里博士曾在密歇根大学（UM）担任工程学教授。2008年，萨斯特里博士被授予亚瑟·F·瑟诺夫教授（UM最高教学荣誉）称号。她早期获得终身教职并得到晋升，在她17年的学术生涯中，获得了她科学领域的一些最高荣誉，包括ASME弗兰克·克雷思能源奖（2011年）和美国国家科学基金会（NSF）总统早期职业奖（1997年）。她创立了两个学术研究中心，分别专注于细胞内信号传导（Keck基金会）和先进汽车电池（通用汽车/能源部），还创立了一个全球能源系统工程研究生项目。她合著了100多篇出版物和100多项专利和申请，并在全球范围内就数学、物理、生命科学和电池技术等广泛的科学和技术主题发表了100多场特邀讲座和研讨会。萨斯特里积极参与慈善事业和商业指导，重点关注教育和扶贫。她拥有康奈尔大学的博士学位和硕士学位，以及特拉华大学的学士学位，均主修机械工程。我们认为，萨斯特里博士在成功公司的工作经验和教育经验使她有资格担任我们的董事会成员。

芭比·布雷弗 - 董事

布雷弗女士（50岁）自2019年7月起担任我们的董事会成员。自2024年11月起，布雷弗女士担任Camunda的首席人力资源官，Camunda是一家企业平台，用于代理编排，使组织能够在复杂、端到端的业务流程中协调人工智能代理、人员和系统。2019年2月至2024年11月，布雷弗女士曾担任Marqeta, Inc.的首席人力资源官。自2017年5月至今，布雷弗女士一直是TNT Consulting LLC的创始人兼首席执行官，这是一家为早期成长型公司提供建议的咨询公司。2017年9月至2019年2月，布雷弗女士曾担任GitLab Inc.的首席文化官，这是一家信息技术和服务公司，使用开源软件创建一个涵盖整个DevOps生命周期的单一应用程序。2011年至2017年，布雷弗女士在Netflix担任人力资源副总裁，负责Netflix的产品创新、工程/开发、业务发展和数字供应链部门的人力资源工作，管理一个支持超过1500名员工的团队。在此之前，2008年4月至2011年1月，布雷弗女士在Sportvision担任人力资源副总裁，Sportvision是一家领先的体育娱乐产品和数据解决方案提供商。2000年至2007年，布雷弗女士在思科担任人力资源经理。她还拥有情景领导力和项目管理的认证。布雷弗女士在圣克拉拉大学获得传播学和商业的学士学位，并以优异成绩毕业。她还拥有乔治华盛顿大学的人力资源管理硕士学位。我们认为，布雷弗女士的管理经验使她有资格担任我们的董事会成员。

有关董事会和公司治理的信息

董事会领导结构

Ann Marie Sastry，博士自2017年11月公司成立起，一直担任我们的首席执行官、总裁和董事会主席。我们认为，这种结构目前对我们和股东来说是最有效的治理框架，因为它使我们的公司能够从Sastry博士作为Amesite创始人的才能、知识和领导力中受益，并使她能够利用在管理公司过程中获得的深入专注和视角，有效地领导我们的董事会。由于Sastry博士在就管理和其他业务方面向董事会和高级管理层提供建议方面有经验，因此她特别适合担任主席。

我们认识到，不同的董事会领导结构可能适用于不同情况的公司。我们将继续持续审查我们的公司治理政策和领导结构，以确保它们继续满足公司的需求。

风险监督中的角色

管理层负责管理我们面临的风险。董事会负责监督管理层设计的风险管理方法，该方法旨在支持组织目标（包括战略目标）的实现，提高长期组织绩效并增强股东价值。董事会全体成员参与审查我们的战略目标和计划，这是董事会评估管理层的风险管理方法和风险容忍度的关键部分。风险管理的基本部分不仅是了解公司面临的风险以及管理层为管理这些风险所采取的措施，还包括了解对我们而言适当的风险水平。在制定我们的业务战略时，我们的董事会评估管理层正在缓解的各种风险，并确定对我们而言适当的风险水平。

股东向董事会的沟通

希望将书面沟通直接提交给董事会或指定董事的股东，应将沟通发送至Amesite公司秘书，地址为密歇根州底特律市Shelby街607号700室PMB 214，收件人为整个董事会或指定的董事。所有股东的沟通都将由我们董事会的独立成员进行考虑。与董事会的职责和责任无关的事项可能会被排除，例如：

\n\n\n\n

●

垃圾邮件和群发邮件；

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	\n
\n	●	简历和其他形式的求职信息；

\n	\n
\n	●	调查；以及

\n	\n
\n	●	游说或广告。

此外，任何性质不当敌对、威胁或非法的材料可能会被排除，但若任何沟通被过滤，可根据要求向任何独立董事提供。

董事或高管涉及某些法律程序

除本文件所述情况外，公司在过去十年中，其董事、高管和董事提名人未涉及任何在S-K条例第401(f)项中描述的法律诉讼。此外，没有任何重大诉讼涉及任何董事、高管或公司的关联方，任何持有公司任何类别的投票证券超过5%的记录所有者或实际所有者，或任何此类董事、高管、公司关联方或股东的关联方作为对公司或其任何子公司不利的一方，或与公司或其任何子公司有重大不利利益。

董事和高管责任保险

公司拥有董事和高管责任保险，该保险为公司的董事和高管在作为董事或高管时的行为或不作为造成的责任提供保障，但受某些排除条款的限制。该保险还为公司提供保障，以弥补其在赔偿高管和董事时可能产生的损失。此外，根据适用法律和公司章程，高管和董事还享有赔偿权利。

董事独立性

纳斯达克资本市场上市规则要求，上市公司的董事会中独立董事必须占多数。此外，纳斯达克资本市场规则要求，除特定例外情况外，上市公司审计、薪酬和公司治理及提名委员会的成员必须是独立的。审计委员会成员还必须符合1934年《证券交易法》（以下简称“证券交易法”）修订后第10A-3条规定的独立性标准。根据纳斯达克资本市场规则，只有在公司董事会认为该人没有可能妨碍其在履行董事职责时独立判断能力的关系时，该董事才能被认定为“独立董事”。

公司董事会已审查了公司董事和董事提名人独立性，并考虑了任何董事是否具有可能影响其履行职责时独立判断能力的重大关系。根据每位董事提供的有关其背景、就业和关联关系（包括家庭关系）的信息，董事会确定，目前代表公司五位董事中的四位的Barbie Brewer、J. Michael Losh、George Parmer和Gilbert S. Omenn，医学博士、哲学博士，根据适用的证券交易委员会（SEC）规则和法规以及纳斯达克资本市场上市标准中对该术语的定义，均为“独立董事”。在做出这些决定时，董事会考虑了每位非雇员董事与公司当前和以前的关系以及董事会认为在确定其独立性时相关的所有其他事实和情况，包括每位非雇员董事对公司股本的受益所有权，以及在标题为“特定关系和关联方交易”的部分中描述的涉及他们的任何交易。

禁止交易

董事和高管\n不得对本公司证券进行对冲，且在有限例外情况下，不得将本公司证券作为任何贷款的抵押品。其他限制详见本公司《内部交易合规计划》，该计划可在 https://ir.amesite.com/corporate-governance/governance-documents 查阅。

内部交易政策

我们已制定内部交易政策（“内部交易政策”），该政策规定了涉及本公司证券的交易，包括普通股、期权、认股权证、优先股、债务证券（如债券、债券和票据）及其他证券的购买、出售和其他转让。我们的内部交易政策适用于我们的董事、高管、员工和代理人（如顾问和独立承包商），这些人员会收到或能够接触到本公司的非公开重大信息，以及与上述人员同住的家庭成员或其他个人，以及与上述人员不同住但其在本公司证券中的交易由上述人员指导或受其影响或控制的家庭成员或其他个人。我们的内部交易政策旨在确保遵守相关的证券交易委员会（SEC）规则和法规，包括内部交易规则，以及纳斯达克适用的上市标准。我们内部交易政策的副本作为我们的2026财年年度报告（10-K表格）的附件19.1提交。

未及时提交16(a)条款报告

《交易法》第16(a)条要求我们的董事、高管和持有我们超过10%普通股的受益所有人向证券交易委员会提交所有权和所有权变化报告。根据提供给我们的这些报告的副本以及书面声明，我们相信这些人在2026财年结束时及时满足了所有适用的16(a)条款报告要求，但以下情况除外：(i) George Parmer（在一份涉及三项交易的4号表上迟交），(ii) Ann Marie Sastry博士（在一份涉及三项交易的4号表上迟交），以及(iii) Sarah Berman（在一份涉及一项交易的4号表上迟交）。

董事会委员会

2020年9月，董事会设立了审计、薪酬和公司治理及提名委员会，每个委员会均由成员组成，并具有以下描述的责任。以下每个委员会都有经公司董事会批准的书面章程，这些章程可在公司网站 https://ir.amesite.com/corporate-governance/governance-documents 上查阅。每个委员会根据其认为适当的方式以及公司董事会可能要求的方式向公司董事会报告。

每个委员会的组成和职能如下所述。

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

姓名

独立

审计

薪酬

公司治理和
\n提名
\n委员会 ⁽¹⁾

Barbie Brewer

J. Michael Losh

Gilbert S. Omenn, M.D., Ph.D.

George Parmer

\n\n\n\n

委员会主席

\n\n\n\n

⁽¹⁾	我们的独立董事履行公司治理和提名委员会的职能。

审计委员会

审计委员会目前由J. Michael Losh、Gilbert S. Omenn、M.D.、Ph.D.和George Parmer组成。Losh先生担任审计委员会主席。公司董事会已确定，审计委员会的每位成员均符合证券交易委员会（SEC）和纳斯达克资本市场上市标准的相关规定和法规对独立性和财务知识的要求。公司董事会还确定，Losh先生是证券交易委员会（SEC）规则中定义的“审计委员会财务专家”，并且符合纳斯达克资本市场上市标准中对财务专业能力的要求。审计委员会的职责包括但不限于：

\n\n

●

选择并聘请独立的会计师事务所对公司的财务报表进行审计；

\n\n

●

监督独立的会计师事务所的工作，并采取其认为必要的措施，以确保会计师与管理层保持独立。

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	●	reviewing financial statements and discussing with management and the independent registered public accounting firm the Company’s annual audited and quarterly financial statements, the results of the independent audit and the quarterly reviews, and the reports and certifications regarding internal control over financial reporting and disclosure controls;

\n	\n
\n	●	preparing the audit committee report that the SEC requires to be included in the Company’s annual proxy statement;

\n	\n
\n	●	reviewing the adequacy and effectiveness of the Company’s internal controls and disclosure controls and procedures, as may be required;

\n	\n
\n	●	overseeing the Company’s policies on risk assessment and risk management, including risk related to cybersecurity;

\n	\n
\n	●	reviewing related party transactions; and

\n	\n
\n	●	approving or, as required, pre-approving, all audit and all permissible non-audit services and fees to be performed by the independent registered public accounting firm.

The\nCompany’s audit committee operates under a written charter which satisfies the applicable rules and regulations of the SEC and the\nlisting standards of The Nasdaq Capital Market. The audit committee met four times during the year ended June 30, 2026.

Compensation Committee

The\nCompany’s compensation committee is currently comprised of Barbie Brewer and Gilbert S. Omenn, M.D., Ph.D. Ms. Brewer serves as\nthe chairperson of the compensation committee. The Company’s board of directors has determined that each member of the compensation\ncommittee meets the requirements for independence under the applicable rules and regulations of the SEC and listing standards of The Nasdaq\nCapital Market. Each member of the compensation committee is a non-employee director as defined in Rule 16b-3 promulgated under the Exchange\nAct. The purpose of the compensation committee is to oversee the Company’s compensation policies, plans and benefit programs and\nto discharge the responsibilities of the Company’s board of directors relating to compensation of its executive officers. The responsibilities\nof the compensation committee include, among other things:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	●	reviewing and approving or recommending to the board of directors for approval compensation of the Company’s executive officers;

\n	\n
\n	●	reviewing and recommending to the board of directors for approval the compensation of directors;

\n	\n
\n	●	overseeing the Company’s overall compensation philosophy and compensation policies, plans and benefit programs for service providers, including the Company’s executive officers;

\n	\n
\n	●	reviewing, approving and making recommendations to the Company’s board of directors regarding incentive compensation and equity plans; and

\n	\n
\n	●	administering the Company’s equity compensation plans.

The compensation committee\ndid not meet in person during the year ended June 30, 2026.

The Role of Management in the Compensation-Setting\nProcess

Management’s role in\nthe compensation-setting process, includes the following:

\n\n\n\n

●

to establish the operating budget approved by the board of directors, which forms the basis for evaluating corporate achievements that are taken into consideration when evaluating compensation levels for Named Executive Officers; and

\n\n\n\n

●

to make recommendations to the Compensation Committee on salary levels and stock option and restricted stock awards (or RSUs).

Management also prepares information\nfor each Compensation Committee meeting. Our Chief Executive Officer also participates in committee meetings at the request of the Compensation\nCommittee to provide, among other things:

\n\n\n\n

●

background information regarding the Company’s strategic objectives; and

\n\n\n\n

●

their evaluation of the performance of the Named Executive Officers, including accomplishments, and areas of strength and weakness.

Corporate Governance and Nominating Committee

The\nindependent directors of the Company’s board of directors serve as the Corporate Governance and Nominating Committee and are responsible\nfor reviewing, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole\nand its individual members. The independent directors of the Company’s board of directors, in evaluating the suitability of individual\ncandidates (both new candidates and current members) and recommending candidates for election, and the board of directors, in approving\n(and, in the case of vacancies, appointing) such candidates, consider many factors, including the following:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	●	diversity of personal and professional background, perspective and experience;

\n	\n
\n	●	personal and professional integrity, ethics and values;

\n	\n
\n	●	experience in corporate management, operations or finance, such as serving as an officer or former officer of a publicly held company, and a general understanding of marketing, finance and other elements relevant to the success of a publicly-traded company in today’s business environment;

\n	\n
\n	●	experience relevant to the Company’s industry and with relevant social policy concerns;

\n	\n
\n	●	experience as a board member or executive officer of another publicly held company;

\n	\n
\n	●	relevant academic expertise or other proficiency in an area of the Company’s operations;

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	●	practical and mature business judgment, including ability to make independent analytical inquiries;

\n	\n
\n	●	promotion of a diversity of business or career experience relevant to the Company’s success; and

\n	\n
\n	●	any other relevant qualifications, attributes or skills.

Currently, the independent\ndirectors evaluate each individual in the context of the board of directors as a whole, with the objective of assembling a group that\ncan best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity\nof experience in these various areas.

The independent directors\nconsider stockholder nominees made in accordance with our bylaws, and evaluate candidates recommended by stockholders in the same manner\nas all other candidates brought to the attention of the independent directors. Stockholder recommendations may be submitted to the independent\ndirectors in care of the Secretary at the address set forth under “Stockholder Communications to the Board of Directors.”\nThe Corporate Governance and Nominating Committee did not meet in person during the year ended June 30, 2026.

Compensation Committee\nInterlocks and Insider Participation

None\nof the Company’s executive officers serves, or in the past has served, as a member of the board of directors or compensation committee,\nor other committee serving an equivalent function, of any entity that has one or more executive officers who serve as members of the Company’s\nboard of directors or its compensation committee. None of the members of the Company’s compensation committee is, or has ever been,\nan officer or employee of the Company.

Code of Business Conduct\nand Ethics

The\nCompany’s board of directors adopted a code of business conduct and ethics applicable to its employees, directors and officers,\nin accordance with applicable U.S. federal securities laws and the corporate governance rules of The Nasdaq Capital Market. The code of\nbusiness conduct and ethics is publicly available on the Company’s website. Any substantive amendments or waivers of the code of\nbusiness conduct and ethics may be made only by the Company’s board of directors and will be promptly disclosed as required by applicable\nU.S. federal securities laws and the corporate governance rules of The Nasdaq Capital Market.

Corporate Governance\nGuidelines

The\nCompany’s board of directors has adopted corporate governance guidelines in accordance with the corporate governance rules of The\nNasdaq Capital Market.

Director Compensation

During the fiscal year ended\nJune 30, 2026, the Company accrued or paid compensation to its directors for serving in such capacity, as shown in the table below. The\nCompany is not aware of any agreements or arrangements between any director or nominee for director, and any person or entity other than\nthe Company, relating to compensation or other payment in connection with such person’s candidacy or service as a director of the\nCompany.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

Name	Fees earned or paid in cash⁽⁵⁾		Stock Awards			Total
Barbie Brewer ⁽¹⁾	$	55,500		$	100,000		$	155,500
J. Michael Losh ⁽²⁾	$	58,000		$	100,000		$	158,000
Gilbert S. Omenn, M.D., Ph.D. ⁽³⁾	$	48,000		$	100,000		$	148,000
George Parmer ⁽⁴⁾	$	48,000		$	100,000		$	148,000

\n\n\n\n

(1)	As of June 30, 2026, Barbie Brewer had 29,932 option awards outstanding.

\n\n\n\n

(2)	As of June 30, 2026, Michael Losh had 34,099 option awards outstanding.

\n\n\n\n

(3)	As of June 30, 2026, Gilbert S. Omenn had 21,342 option awards outstanding.

\n\n\n\n

(4)	As of June 30, 2026, George Parmer had 4,259 option awards outstanding.

\n\n\n\n

(5)	This annual cash retainer was largely elected to be deferred into a number of stock units as calculated per the terms of the Company’s Deferred Fee plan, which vest upon termination of service.

On May 22, 2021, the board\nof directors adopted a director compensation program for the Company’s independent directors consisting of equity compensation,\nbeginning in fiscal year 2021. Directors who are also officers do not receive any additional compensation for serving on any board committees.\nThese programs consist of the following equity compensation for independent directors:

Cash and Equity Compensation

On September 29, 2021, the\nboard of directors approved changes to our director compensation program for fiscal year 2022 and beyond. The board instituted an annual\ncash retainer for our directors in an amount of $48,000, provided that the cash retainer for the chair of our Compensation Committee and\nAudit Committee shall also contain an additional retainer of $7,500 and $10,000, respectively. In addition, our directors received an\nannual $100,000 restricted stock unit grant, which will vest on the one-year anniversary of grant. Cash and equity payments for director\nservice are paid on a quarterly basis.

Finally, our board of directors\nadopted a Deferred Fee Plan for our non-employee directors pursuant to which directors may defer all or a portion of their total cash\ncompensation into deferred stock units which will be payable to them on the earlier of, their departure from the board or a change in\ncontrol. Directors make an annual election before the start of the calendar year regarding what portion of cash compensation will be deferred\nfor the subsequent calendar year.

Interests of Executive Officers and Directors\nin this Proposal

Except for our current director\nnominees, our executive officers, directors and associates of our executive officers, directors and director nominees do not have any\nsubstantial interest, direct or indirect, in this proposal.

Required Vote of Stockholders

A plurality of the votes cast\nat the Annual Meeting is required to elect a nominee as a director.

Board Recommendation

The board of directors unanimously\nrecommends a vote “FOR” the election of Gilbert S. Omenn, M.D., Ph.D. and George Parmer as directors of the\nCompany.

PROPOSAL 2:

RATIFICATION OF THE APPOINTMENT OF THE INDEPENDENT\nREGISTERED PUBLIC ACCOUNTING FIRM

Our board of directors has\nselected Novogradac & Company LLP (“Novogradac”) to audit our financial statements for the fiscal year ending June 30,\n2027. A representative of Novogradac is not expected to attend the Annual Meeting.

Although stockholder approval\nof the selection of Novogradac is not required by law, our board of directors believes it is advisable to give stockholders an opportunity\nto ratify this selection. If this proposal is not approved at the Annual Meeting, the board of directors may reconsider its selection\nof Novogradac.

On June 24, 2025, we dismissed\nTurner, Stone & Company, L.L.P. (“Turner”) as our independent registered public accounting firm. The decision to terminate\nTurner was made with the recommendation and approval of the Audit Committee of our board of directors. The reports of Turner on our financial\nstatements for each of fiscal years ended June 30, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion, nor were\nthey qualified or modified as to uncertainty, audit scope or accounting principle, except that Turner’s audit report dated September\n30, 2024 related to our financial statements for the year ended June 30, 2024 contained an explanatory paragraph as to the uncertainty\nof our ability to continue as a going concern. During the fiscal years ended June 30, 2024 and 2023, and the subsequent interim period\nthrough June 26, 2025, there were no disagreements (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions)\nbetween us and Turner on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures\nthat, if not resolved to Turner’s satisfaction, would have caused Turner to make reference to the subject matter of the disagreement\nin connection with its audit reports.

We provided Turner with a\ncopy of the disclosure required by Item 304(a) of Regulation S-K prior to its filing with the Securities and Exchange Commission and requested\nthat Turner furnish a letter addressed to the Securities and Exchange Commission stating whether it agrees with such statements. A copy\nof Turner’s letter, dated June 24, 2025 is filed as Exhibit 16.1 to the Current Report on Form 8-K filed with the Securities and\nExchange Commission on June 26, 2025. A representative of Turner is not expected to attend the Annual Meeting.

On June 24, 2025, we appointed\nNovogradac as our new independent registered public accounting firm effective as of June 24, 2025. The Audit Committee of our board of\ndirectors approved the appointment of Novogradac.

During the fiscal year ended\nJune 30, 2026, neither the Company, nor anyone acting on its behalf, consulted with Novogradac regarding (i) the application of accounting\nprinciples to a specified transaction, either completed or proposed, or the type of audit opinion that may be rendered on the Company’s\nfinancial statements, and Novogradac did not provide either a written report or oral advice to the Company that was an important factor\nconsidered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue, or (ii) any matter that\nwas either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable\nevent (as described in Item 304(a)(1)(v) of Regulation S-K).

Fees of Independent Registered Public Accounting\nFirms

Novogradac\nacted as our independent registered public accounting firm for the years ended June 30, 2026 and June 30, 2025. Turner acted as\nour independent registered public accounting firm for certain interim periods through March 31, 2025. The following table shows the fees\nthat were incurred by us for audit and other services provided by Novogradac and Turner for the years ended June 30, 2026 and 2025.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

	Years Ended June 30,
	2026		2025
Audit Fees ^(a)	$	116,655		$	96,600
Audit-Related Fees ^(b)		-			12,500
Tax Fees ^(c)		4,375			10,349
Other Fees ^(d)		-			30,813
Total	$	121,030		$	150,262

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

(a)	Audit fees include fees for professional services provided in connection with the audit of the Company’s annual financial statements, the review of its financial statements included in the Company’s Quarterly Reports on Form 10-Q and services that are normally provided by the independent registered accounting firm for statutory and regulatory filings or engagements in the indicated fiscal year.

(b)	Audit-related include the fees for assurance and related services by the independent registered accounting firm that are reasonably related to the performance of the audit or review of the company’s financial statements.

(c)	Tax fees represent fees for professional services related to tax compliance, tax advice and tax planning.

(d)	Other fees represent fees for any other products and services provided by the independent registered accounting firm, including those related to our filing of certain registration statements.

Pre-Approval Policies and Procedures

All services described above\nrendered by Novogradac and Turner were pre-approved by our board of directors. The board of directors has adopted a pre-approval policy\nthat provides for the pre-approval by the audit committee of all services performed for us by our independent registered public accounting\nfirm. Our independent registered public accounting firm and management are required to periodically report to the board of directors regarding\nthe extent of services provided by the independent registered public accounting firm in accordance with this pre-approval, and the fees\nfor the services performed to date.

Interests of Executive Officers and Directors\nin this Proposal

Our executive officers, directors\nand director nominees, and associates of our executive officers, directors and director nominees do not have any substantial interest,\ndirect or indirect, in this proposal.

Required Vote of Stockholders

The affirmative vote of a\nmajority of the votes cast by the stockholders entitled to vote on the matter is required to ratify the appointment of the independent\nregistered public accounting firm.

Board Recommendation

The board of directors unanimously\nrecommends a vote “FOR” the ratification of the appointment of Novogradac as our independent registered public\naccounting firm.

PROPOSAL 3:

REVERSE STOCK SPLIT

Our board of directors has\napproved an amendment to our Certificate of Incorporation to combine the outstanding shares of our common stock into a lesser number of\noutstanding shares (a “Reverse Stock Split”). If approved by the stockholders as proposed, the board of directors would have\nthe sole discretion to effect the Reverse Stock Split, if at all, within one (1) year of the date the proposal is approved by stockholders\nand to fix the specific ratio for the combination within a range of one-for-two (1-for-2) to a maximum of a one-for-two hundred fifty\n(1-for-250) split. The board of directors has the discretion to abandon the amendment and not implement the Reverse Stock Split. We believe\nthat enabling the board of directors to fix the specific ratio of the Reverse Stock Split within the stated range will provide us with\nthe flexibility to implement it in a manner designed to maximize the anticipated benefits for our stockholders.

In\nfixing the ratio, the board of directors may consider, among other things, factors such as: the initial and continued listing requirements\nof the Nasdaq Capital Market; the number of shares of our common stock outstanding; potential financing opportunities; and prevailing\ngeneral market and economic conditions.

Reasons for the Reverse Stock Split

The Company’s primary reasons\nfor approving and recommending the Reverse Stock Split are to increase the per share price and bid price of our common stock to comply\nwith the listing requirements of Nasdaq.

Potential Effects of the Proposed Amendment

If our stockholders approve\nthe Reverse Stock Split and the board of directors effects it, the number of shares of common stock issued and outstanding will be reduced,\ndepending upon the ratio determined by the board of directors. The Reverse Stock Split will affect all holders of our common stock uniformly\nand will not affect any stockholder’s percentage ownership interest in the Company, except that as described below in “Fractional\nShares,” record holders of common stock otherwise entitled to a fractional share as a result of the Reverse Stock Split because they\nhold a number of shares not evenly divisible by the Reverse Stock Split ratio will automatically be entitled to receive an additional\nfraction of a share of common stock to round up to the next whole share. In addition, the Reverse Stock Split will not affect any stockholder’s\nproportionate voting power (subject to the treatment of fractional shares).

The Reverse Stock Split will\nnot change the terms of the common stock. Additionally, the Reverse Stock Split will have no effect on the number of common stock that\nwe are authorized to issue. After the Reverse Stock Split, the shares of common stock will have the same voting rights and rights to dividends\nand distributions and will be identical in all other respects to the common stock now authorized. The common stock will remain fully paid\nand non-assessable.

After the effective time of\nthe Reverse Stock Split, we will continue to be subject to the periodic reporting and other requirements of the Exchange Act.

Registered “Book-Entry” Holders of\nCommon Stock

Our registered holders of\ncommon stock hold some or all of their shares electronically in book-entry form with the transfer agent. These stockholders do not have\nstock certificates evidencing their ownership. They are, however, provided with statements reflecting the number of shares registered\nin their accounts.

Stockholders who hold shares\nelectronically in book-entry form with the transfer agent will not need to take action to receive evidence of their shares of post-Reverse\nStock Split common stock.

Holders of Certificated Shares of Common Stock

Stockholders holding shares\nof our common stock in certificated form will be sent a transmittal letter by the transfer agent after the effective time of the Reverse\nStock Split. The letter of transmittal will contain instructions on how a stockholder should surrender his, her or its certificate(s)\nrepresenting shares of our common stock (the “Old Certificates”) to the transfer agent. Unless a stockholder specifically\nrequests a new paper certificate or holds restricted shares, upon the stockholder’s surrender of all of the stockholder’s Old Certificates\nto the transfer agent, together with a properly completed and executed letter of transmittal, the transfer agent will register the appropriate\nnumber of shares of post-Reverse Stock Split common stock electronically in book-entry form and provide the stockholder with a statement\nreflecting the number of shares registered in the stockholder’s account. No stockholder will be required to pay a transfer or other fee\nto exchange his, her or its Old Certificates.

STOCKHOLDERS SHOULD NOT DESTROY ANY STOCK CERTIFICATE(S)\nAND SHOULD NOT SUBMIT ANY STOCK CERTIFICATE(S) UNTIL REQUESTED TO DO SO.

Fractional Shares

We will not issue fractional\nshares in connection with the Reverse Stock Split. Instead, stockholders who otherwise would be entitled to receive fractional shares\nbecause they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will automatically be entitled to receive an\nadditional fraction of a share of common stock to round up to the next whole share. In any event, cash will not be paid for fractional\nshares.

Effect of the Reverse Stock Split on Outstanding\nStock Options and Warrants

Based upon the Reverse Stock\nSplit ratio, proportionate adjustments are generally required to be made to the per share exercise price and the number of shares issuable\nupon the exercise of all outstanding options and warrants. This would result in approximately the same aggregate price being required\nto be paid under such options or warrants upon exercise, and approximately the same value of shares of common stock being delivered upon\nsuch exercise immediately following the Reverse Stock Split as was the case immediately preceding the Reverse Stock Split. The number\nof shares reserved for issuance pursuant to these securities will be reduced proportionately based upon the Reverse Stock Split ratio.

Accounting Matters

The proposed amendment to\nour Certificate of Incorporation will not affect the par value of our common stock. As a result, at the effective time of the Reverse\nStock Split, the stated capital on our balance sheet attributable to the common stock will be reduced in the same proportion as the Reverse\nStock Split ratio, and the additional paid-in capital account will be credited with the amount by which the stated capital is reduced.\nThe per share net income or loss will be restated for prior periods to conform to the post-Reverse Stock Split presentation.

Certain Federal Income Tax Consequences of\nthe Reverse Stock Split

The Reverse Stock Split is\nintended to qualify as a “reorganization” under Section 368 of the Internal Revenue Code of 1986, as amended (the “Code”),\nthat should constitute a “recapitalization” for U.S. federal income tax purposes. Assuming the Reverse Stock Split qualifies\nas a reorganization, a U.S. holder generally will not recognize gain or loss upon the exchange of our ordinary shares for a lesser number\nof ordinary shares, based upon the Reverse Stock Split ratio. A U.S. holder’s aggregate tax basis in the lesser number of ordinary shares\nreceived in the Reverse Stock Split will be the same such U.S. holder’s aggregate tax basis in the shares of our common stock that such\nU.S. holder owned immediately prior to the Reverse Stock Split. The holding period for the ordinary shares received in the Reverse Stock\nSplit will include the period during which a U.S. holder held the shares of our common stock that were surrendered in the Reverse Stock\nSplit.

THE FOREGOING IS INTENDED\nONLY AS A SUMMARY OF CERTAIN FEDERAL INCOME TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT, AND DOES NOT CONSTITUTE A TAX OPINION. EACH HOLDER\nOF OUR COMMON SHARES SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT TO THEM AND FOR REFERENCE\nTO APPLICABLE PROVISIONS OF THE CODE.

Interests of Executive Officers and Directors\nin this Proposal

Required Vote of Stockholders

The affirmative vote of a\nmajority of the votes cast by the stockholders entitled to vote on the matter is required to approve this proposal.

Board Recommendation

The board of directors unanimously\nrecommends a vote “FOR” Proposal 3.

PROPOSAL 4:

AUTHORIZATION TO ISSUE SECURITIES IN ONE OR\nMORE NON-PUBLIC OFFERINGS IN

ACCORDANCE WITH NASDAQ MARKETPLACE RULE 5635(D)

Our common stock is listed\non The Nasdaq Capital Market, and, as such, we are subject to the Nasdaq Marketplace Rules. Nasdaq Marketplace Rule 5635(d) requires stockholder\napproval prior to the issuance of securities in a transaction, other than a public offering, involving the sale, issuance, or potential\nissuance by us of common stock (or securities convertible into or exercisable for common stock), which equals 20% or more of the common\nstock or 20% or more of the voting power outstanding before the issuance, at a price less than the lower of: (i) the closing price immediately\npreceding the signing of the binding agreement, or (ii) the average closing price of the common stock for the five trading days immediately\npreceding the signing of the binding agreement for the transaction.

We may seek to raise additional\ncapital to implement our business strategy and enhance our overall capitalization. We have not determined the particular terms for such\nprospective offerings. Because we may seek additional capital that triggers the requirements of Rule 5635(d), we are seeking stockholder\napproval now, so that we will be able to move quickly to take full advantage of any opportunities that may develop in the equity markets.

We are seeking stockholder\napproval for the potential issuance of shares of our common stock, or securities convertible into our common stock, in one or more capital-raising\ntransactions, or offerings, subject to the following limitations:

The aggregate number of shares\nissued in the offerings will not exceed the number of shares that would result in aggregate proceeds of up to $25 million at a discount\nof no more than 80% to market (including pursuant to preferred stock, options, warrants, convertible debt, or other securities exercisable\nfor or convertible into common stock), subject to adjustment for any reverse stock split effected prior to the offerings. Such offerings\nwill occur, if at all, within one year after the date of approval, and such other terms as our Board shall deem to be in the best interests\nof the Company and its stockholders, not inconsistent with the foregoing.

The issuance of shares of\nour common stock, or other securities convertible into shares of our common stock, in accordance with any offerings would dilute, and\nthereby reduce, each existing stockholder’s proportionate ownership in our common stock.

The issuance of shares of\ncommon stock in one or more non-public offerings could have an anti-takeover effect. Such issuance could dilute the voting power of a\nperson seeking control of the Company, thereby deterring or rendering more difficult a merger, tender offer, proxy contest, or an extraordinary\ncorporate transaction opposed by the Company.

Our Board has not yet determined\nthe terms and conditions of any offerings. As a result, the level of potential dilution cannot be determined at this time. It is possible\nthat if we conduct a non-public stock offering, some of the shares we sell could be purchased by one or more investors who could acquire\na large block of our common stock. This would concentrate voting power in the hands of a few stockholders who could exercise greater influence\non our operations or the outcome of matters put to a vote of stockholders in the future.

We cannot determine what the\nactual net proceeds of the offerings will be until they are completed. If all or part of the offerings are completed, the net proceeds\nwill be used for general corporate purposes. We currently have no arrangements or understandings regarding any specific transaction with\ninvestors, so we cannot predict whether we will be successful should we seek to raise capital through any offerings.

Interests of Executive Officers and Directors\nin this Proposal

Required Vote of Stockholders

The affirmative vote of a\nmajority of the votes cast by the stockholders entitled to vote on the matter is required to approve Proposal No. 4.

Board Recommendation

The board of directors unanimously\nrecommends a vote “FOR” Proposal 4.

PROPOSAL 5:

ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION

Section 14A of the Exchange\nAct and the related rules of the SEC require that we provide our stockholders with the opportunity to vote, on a non-binding, advisory\nbasis, on the compensation of our named executive officers (commonly referred to as a “say-on-pay” vote). This proposal, commonly\nknown as a “say-on-pay” proposal, gives our stockholders the opportunity to express their views on our named executive officers’\ncompensation as disclosed in this Proxy Statement. This vote is not intended to address any specific item of compensation, but rather\nthe overall compensation of our named executive officers and the philosophy, policies and practices described in this Proxy Statement.

As described in detail under\nthe heading “Executive Compensation” above, our executive compensation program is designed to attract, retain and motivate talented\nexecutive officers and to align the interests of our executive officers with the interests of our stockholders. We encourage stockholders\nto review the Executive Compensation section of this Proxy Statement, including the Summary Compensation Table and other related tables\nand narrative disclosure, which describe the compensation of our named executive officers for the fiscal year ended June 30, 2026.

This proposal gives our stockholders\nthe opportunity to express their views on the compensation of our named executive officers by voting to approve or not approve such compensation\nthrough the following resolution:

“RESOLVED, that the stockholders\nof Amesite Inc. approve, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in this Proxy\nStatement pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative disclosure.”

Because this vote is advisory,\nit will not be binding upon the board of directors or the Compensation Committee, will not overrule any decisions made by the board of\ndirectors or the Compensation Committee, and will not create or imply any additional fiduciary duty on the part of the board of directors.\nHowever, the board of directors and the Compensation Committee value the opinions expressed by stockholders and will consider the outcome\nof the vote when making future executive compensation decisions.

Interests of Executive Officers and Directors\nin this Proposal

Our executive officers have\nan interest in this proposal because it relates to the compensation of our Named Executive Officers.

Required Vote of Stockholders

The affirmative vote of a\nmajority of the votes cast by the stockholders entitled to vote on the matter is required to approve, on an advisory basis, the compensation\nof our named executive officers.

Board Recommendation

The board of directors unanimously\nrecommends a vote “FOR” Proposal 5.

PROPOSAL 6:

ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY\nVOTES ON EXECUTIVE COMPENSATION

In addition to the say-on-pay\nvote described in Proposal 5 above, Section 14A of the Exchange Act and the related rules of the SEC also require that we provide our\nstockholders the opportunity to indicate, on a non-binding, advisory basis, how frequently we should seek future advisory votes on the\ncompensation of our named executive officers, such as Proposal 5 above. By voting on this Proposal 6, stockholders may indicate whether\nthey would prefer that we conduct future advisory votes on executive compensation once every one, two or three years.

After consideration of the\nbenefits and consequences of each alternative, our board of directors recommends that future advisory votes on executive compensation\nbe held every year. We believe that an annual advisory vote on executive compensation will allow our stockholders to provide us with their\ndirect input on our compensation philosophy, policies and practices as disclosed in our proxy statement every year, which is consistent\nwith our goal of maintaining good communication with our stockholders on executive compensation matters.

Stockholders are not voting\nto approve or disapprove the board of directors’ recommendation. Instead, stockholders may indicate their preferred voting frequency by\nselecting the option of one year, two years or three years, or they may abstain from voting, when voting on the following resolution:

“RESOLVED, that the stockholders\nof Amesite Inc. determine, on an advisory basis, that the frequency with which the stockholders shall have an advisory vote on the compensation\nof the Company’s named executive officers, as disclosed pursuant to the SEC’s compensation disclosure rules, shall be:

Choice 1 - every year;

Choice 2 - every two years;

Choice 3 - every three years;\nor

Choice 4 - abstain from voting.”

Because this vote is advisory,\nit will not be binding upon the board of directors. However, the board of directors and the Compensation Committee value the opinions\nexpressed by stockholders and will consider the outcome of the vote when determining the frequency of future advisory votes on executive\ncompensation.

Interests of Executive Officers and Directors\nin this Proposal

Required Vote of Stockholders

The frequency option - one\nyear, two years or three years - receiving the greatest number of votes cast by the stockholders entitled to vote on the matter will be\nconsidered the frequency preferred by our stockholders. Because this vote is advisory and not binding on the board of directors or the\nCompany in any way, the board of directors may decide that it is in the best interests of our stockholders to hold an advisory vote on\nexecutive compensation more or less frequently than the frequency receiving the most votes cast by our stockholders.

Board Recommendation

The board of directors unanimously\nrecommends a frequency of “EVERY YEAR” for future advisory votes on the compensation of our named executive officers.

AUDIT COMMITTEE REPORT

The following Audit Committee\nReport shall not be deemed to be “soliciting material,” nor deemed to be “filed” with the SEC or subject to the\nliabilities of Section 18 of the Exchange Act. Notwithstanding anything to the contrary set forth in any of the Company’s previous\nfilings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act that might incorporate by\nreference future filings, including this Proxy Statement, in whole or in part, the following Audit Committee Report shall not be incorporated\nby reference into any such filings.

We have reviewed and discussed\nthe Company’s audited financial statements as of and for the fiscal year ended June 30, 2026 with management and with the Company’s\nindependent registered public accounting firm, Novogradac & Company LLP (“Novogradac”).

We have discussed with Novogradac\nthe matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (the “PCAOB”)\nand the SEC.

We have received the written\ndisclosures and the letter from Novogradac required by applicable requirements of the PCAOB regarding Novogradac’s communications\nwith the Audit Committee concerning independence, and we have discussed with Novogradac such firm’s independence from management\nand the Company.

Based on the review and discussions\nreferred to above, we recommended to the Board of Directors that the audited financial statements referred to above be included in the\nCompany’s Annual Report on Form 10-K for the fiscal year ended June 30, 2026, for filing with the SEC.

The Audit Committee is currently\ncomprised of three independent directors (as defined under Nasdaq Listing Rule 5605(a)(2)): J. Michael Losh, George Parmer and Gilbert\nS. Omenn, M.D., Ph.D. The Audit Committee operates under a written charter, which is available on our website at https://ir.amesite.com/corporate-governance/governance-documents.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

Submitted by the Audit Committee

J. Michael Losh - Chairman
Gilbert S. Omenn, M.D., Ph.D.
George Parmer

EXECUTIVE OFFICERS

The\ntable below identifies and sets forth certain biographical and other information regarding our executive officers as of date of this proxy\nstatement. There are no family relationships among any of our executive officers, directors or director or officer nominees. The Company\nis not aware of any arrangement or understanding with another person under which such executive officers were selected as an executive\nofficer.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

Name	Age	Position(s)

Ann Marie Sastry, Ph.D.	59	Chief Executive Officer, President and Chairman of the Board

Sarah Berman	40	Principal Financial and Accounting Officer

Ann Marie Sastry, Ph.D. - President,\nChief Executive Officer and Chairman of the Board of Directors

Dr. Sastry’s biographical\ninformation is set forth above under “Proposal No. 1 - Election of Directors.”

Sarah Berman - Principal Financial and\nAccounting Officer

Ms. Berman has served as our\nPrincipal Financial and Accounting Officer since December 15, 2024. Ms. Berman is a Certified Public Accountant and has extensive experience\nin accounting, auditing and record-keeping for public and private companies. In June 2019, Ms. Berman founded Better Books Consulting\n(“Better Books”), an accounting advisory firm. Prior to Better Books, Ms. Berman served as Senior Accountant at Big Red’s\nEquipment from January 2018 through June 2019. Ms. Berman also previously served as Senior Audit Manager at Turner, Stone & Company,\nL.L.P. (“Turner Stone”) from 2015 through 2017. She also previously served as Audit Manager at Turner Stone from 2012 through\n2015 and as a member of the Audit Staff from 2008 through 2011.

EXECUTIVE COMPENSATION

Summary Compensation Table

The following table sets forth\nthe total compensation paid or accrued during the fiscal years ended June 30, 2026 and 2025 to (i) our Chief Executive Officer, (ii) the\ntwo most highly compensated individuals who were serving as executive officers as of June 30, 2026, and (iii) two additional individuals\nfor whom disclosure would have been provided pursuant to prong (ii) but for the fact that they were not serving as an executive officer\nas of June 30, 2026 (we refer to these individuals as the “Named Executive Officers”).

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

Name and Principal Position	Year	Salary		Bonus			Stock \nAwards		Option Awards (1)	Total
Ann Marie Sastry, Ph.D.	2026	$	550,000		$	-		$	-	$	-	$	550,000
Chief Executive Officer and President	2025	$	550,000		$	-		$	-	$	-	$	550,000

Sarah Berman	2026	$	75,000		$	-		$	-	$	11,400	$	86,400
Principal Financial and Accounting Officer	2025	$	29,155		$	-		$	-	$	6,425	$	35,580

Brandon Owens	2026	$	183,414		$	-		$	-	$	-	$	183,414
Former Vice President of Sales ⁽²⁾	2025	$	158,364		$	-		$	-	$	77,100	$	235,464

\n\n\n\n

(1)

Amounts shown in this column do not reflect dollar amounts actually received. Instead, these amounts represent the aggregate grant date fair value of stock option awards determined in accordance with FASB ASC Topic 718. The assumptions used in the valuation of these awards are set forth in the notes to our financial statements, which are included in our Annual Report on Form 10-K, filed with the SEC on September 23, 2026.

\n\n\n\n

(2)	Mr. Owens served as the Company’s Vice President of Sales from November 2020 until May 2026.

Employment Agreements

Ann Marie Sastry,\nChief Executive Officer

On\nApril 27, 2018 Amesite Parent entered into an Executive Employment Agreement with Dr. Sastry (the “Sastry Employment Agreement”).\nPursuant to the terms of the Sastry Employment Agreement, Dr. Sastry is entitled to a $350,000 base salary to be paid in accordance with\nour regularly established payroll practice. Additionally, Dr. Sastry received a bonus of $200,000 for the year ended June 30, 2019 based\nupon achievement of certain performance milestones (with determination of achievement of such milestones approved by the Compensation\nCommittee of our board of directors). Dr. Sastry is also eligible to receive other customary benefits, including paid time off, health\ninsurance, and other benefits. Dr. Sastry’s base salary is reviewed periodically by our board of directors and adjustments may be\nmade upon the recommendations of the Compensation Committee.

We\nentered into an Executive Agreement, effective June 1, 2020, with Dr. Sastry regarding her continued service as our Chief Executive Officer\n(the “May 2020 Sastry Employment Agreement”). This agreement replaced and superseded the Sastry Employment Agreement. Pursuant\nto the terms of the May 2020 Sastry Employment Agreement, Dr. Sastry was entitled to a $350,000 base salary (the “Base Salary”)\nto be paid in accordance with our regularly established payroll practice, which increased to $550,000 per year upon completion of our\ninitial public offering. Additionally, Dr. Sastry received 525,000 options to purchase our common stock, and is entitled to receive additional\ngrants of options each successive year she serves as Chief Executive Officer based on her Base Salary. Dr. Sastry is also eligible to\nearn an annual bonus of up to $300,000, based on the achievement of certain performance-based milestones for each fiscal year mutually\nagreed upon by our board of directors and/or our Compensation Committee and Dr. Sastry.

Pursuant\nto the May 2020 Sastry Employment Agreement, except in situations where the employment of Dr. Sastry is terminated for Cause (as defined\nin the May 2020 Sastry Employment Agreement), due to death or Disability (as that term is defined in the May 2020 Sastry Employment Agreement),\nor in the case that Dr. Sastry voluntarily resigns without Good Reason (as defined in the 2020 Sastry Employment Agreement), in the event\nthat we terminate Dr. Sastry’s employment at any time without Cause, Dr. Sastry will receive on the date of termination, if Dr.\nSastry instructs the Company in writing, a lump sum amount equal to (A) any portion of unpaid Base Compensation (as defined in the May\n2020 Sastry Employment Agreement) then due for periods prior to the effective date of termination; (B) any Bonus (as defined in the May\n2020 Sastry Employment Agreement) earned and not yet paid through the date of termination; and (C) within 2-1/2 months following submission\nof proper expense reports by Dr. Sastry, all expenses reasonably and necessarily incurred by Dr. Sastry in connection with the business\nof the Company prior to the date of termination; and, provided that Dr. Sastry executes a written release of any and all claims against\nthe Company and all related parties with respect to all matters arising out of Dr. Sastry’s engagement by the Company, the Company\nshall pay to Dr. Sastry the Base Compensation and reimburse Dr. Sastry’s payment of COBRA premiums for twelve (12) months from the\ndate of termination.

Additionally,\nsubject to the limitations described in the May 2020 Sastry Employment Agreement, in the event of Dr. Sastry’s termination of engagement\nwith the Company either (i) by the Company without Cause or Dr. Sastry for Good Reason at any time within six (6) months prior to the\nconsummation of a Change of Control if, prior to or as of such termination, a Change of Control transaction was Pending (as defined in\nthe May 2020 Sastry Employment Agreement) at any time during such six (6)-month period, (ii) by Dr. Sastry for Good Reason at any time\nwithin twelve (12) months after the consummation of a Change of Control, or (iii) by the Company without Cause at any time within twelve\n(12) months after the consummation of a Change of Control, then, Dr. Sastry shall be entitled to the following payments and other benefits:

(i)\non the date of termination (except as specified in clause (C)), the Company shall pay to Dr. Sastry, if Dr. Sastry instructs the Company\nin writing, a lump sum amount equal to (A) any portion of unpaid Base Compensation then due for periods prior to the effective date of\ntermination; (B) any Bonus earned and not yet paid through the date of termination; and (C) within 2-1/2 months following submission of\nproper expense reports by Dr. Sastry, all expenses reasonably and necessarily incurred by Dr. Sastry in connection with the business of\nthe Company prior to the date of termination;

(ii)\non the date of termination the Company shall pay to Dr. Sastry, if Dr. Sastry instructs the Company in writing, a lump sum amount equal\nto twelve (12) months of Dr. Sastry’s Base Compensation then in effect as of the day of termination and reimburse Dr. Sastry for\nthe COBRA premiums she pays to maintain health insurance coverage for twelve (12) months following the date of termination; and

(iii)\nnotwithstanding any provision of any stock incentive plan, stock option agreement, realization bonus, restricted stock agreement or other\nagreement relating to capital stock of the Company, all of the shares that are then unvested shall immediately vest and, with respect\nto all options, warrants and other convertible securities of the Company beneficially held Dr. Sastry, become fully exercisable for (A)\na period of six months following the date of termination only if at the time of such termination there is a Change of Control transaction\nPending or (B) if clause (A) does not apply, then such period of time set forth in the agreement evidencing the security.

Dr.\nSastry is also eligible to receive other customary benefits offered by the Company to its senior executives and directors, including paid\ntime off, retirement benefits, health insurance, life insurance and other benefits. Dr. Sastry’s base salary is reviewed periodically\nby our board of directors and adjustments may be made upon the recommendation of the Compensation Committee.

Sarah Berman, Principal\nFinancial and Accounting Officer

On\nNovember 20, 2024, the Company entered into a CFO Agreement with Ms. Berman (the “Berman CFO Agreement”). Pursuant to the\nBerman CFO Agreement, Ms. Berman shall serve as the Principal Financial and Accounting Officer of the Company for a term of one year commencing\non December 15, 2024 at a fixed monthly fee of $4,000. On October 14, 2025 the agreement was amended to provide for a fixed monthly fee\nof $7,000.

Brandon Owens, Former\nVice President of Sales

On October 12, 2020 the Company\nentered into an employment agreement with Mr. Owens, which was subsequently amended on January 13, 2023 (the “Owens Employment Agreement”).\nPursuant to the terms of the Owens Employment Agreement, as amended, Mr. Owens was entitled to a $150,000 base salary to be paid in accordance\nwith our regularly established payroll practice. Additionally, Mr. Owens was eligible for certain bonus and commission payments during\nhis first year of employment based upon achievement of certain performance milestones. Additionally, Mr. Owens received stock options\nin connection with the commencement of his employment, and was also eligible to receive other customary benefits, stock options, restricted\nstock units and other equity incentive grants as determined by the board of directors. The Owens Employment Agreement was terminated in\nMay 2026.

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth\ninformation regarding outstanding stock options held by our named executive officers as of June 30, 2026:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

NAME	GRANT DATE	VESTING COMMENCEMENT DATE	NUMBER OF SECURITIES UNDERLYING UNEXERCISED OPTIONS (#) EXERCISABLE⁽¹⁾		NUMBER OF SECURITIES UNDERLYING UNEXERCISED OPTIONS (#) UNEXERCISABLE⁽²⁾		OPTION EXERCISE PRICE ($)		OPTION EXPIRATION DATE

Ann Marie Sastry, Ph.D.	5/21/2020	5/21/2021		43,750		-		$	24.00	5/21/2030
Sarah Berman	5/23/2025	5/23/2026		677		1,823		$	3.05	5/23/2035
	6/29/2026	6/29/2027		-		10,000		$	1.14	6/29/2036
Brandon Owens	11/4/2020	11/4/2021		1,667		-		$	49.92	11/4/2030
	5/13/2021	5/13/2022		2,083		-		$	26.28	5/13/2031
	5/23/2025	5/23/2026		-		30,000		$	3.05	5/19/2026

\n\n

(1)

Fully vested.

\n\n

(2)

25% of the options vest on the\none-year anniversary of the date of the grant and the remaining 75% vest in thirty-six (36) successive equal monthly installments thereafter.

Potential Payments Upon Termination or Change in Control:

Please refer to “Executive\nCompensation - Employment Agreements” for information relating to the potential payments to Dr. Sastry upon termination or a change\nin control of the Company.

Clawback Policy

Our board of directors adopted a compensation recovery policy (the “Clawback Policy”), designed to comply with Rule 10D-1 of the Exchange Act and Nasdaq Listing Rule 5608, which provides for recoupment of incentive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under the relevant securities laws. The policy applies to our current and former executive officers. Compensation (as defined in the Clawback Policy) that is granted, earned or vested maybe subject to recoupment. As of the date of this proxy statement, the Company has not been required to prepare an accounting restatement that required the recovery of erroneously awarded compensation pursuant to the Clawback Policy.

Company Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information

The Company does not grant stock options or similar awards to Section 16 Insiders or others who directly report to the CEO in anticipation of the release of material nonpublic information that is likely to result in changes to the price of the Company’s stock, such as a significant positive or negative earnings announcement, or time the public release of such information based on stock option grant dates. In addition, the Company does not grant stock options or similar awards during the four business days prior to or the one business day following the filing of our periodic reports or the filing or furnishing of a Current Report on Form 8-K that discloses material nonpublic information. These restrictions do not apply to RSUs or other types of equity awards that do not include an exercise price related to the market price of the Company’s stock on the date of grant. The Company’s executive officers would not be permitted to choose the grant date for any stock option grants.

Pay versus Performance

Year	Summary Compensation Table Total for PEO ($)(1)		Compensation Actually Paid to PEO ($)(4)			Average Summary Compensation Table Total for Non-PEO NEOs ($)(2)		Average Compensation Actually Paid to Non-PEO NEOs ($)(5)	Value of Initial Fixed $100 Investment Based on Total Shareholder Return (%)(3)		Net Loss ($) (in thousands)
2026	$	560,500		$	560,500		$	137,081	$	103,328		44	%	$	(3,096	)
2025	$	560,032		$	560,032		$	181,621	$	174,485		90	%	$	(6,617	)

(1)	Ann Marie Sastry, Ph.D. was the Company’s Principal Executive Officer (PEO) for each of the 2026 and 2025 fiscal years.

(2)	Sarah Berman and Brandon Owens were Non-PEO Named Executive Officers (NEO) of the Company for the 2026 fiscal year. Sarah Berman, Kalie Wortinger, and Brandon Owens were Non-PEO Named Executive Officers (NEO) of the Company for the 2025 fiscal year.

(3)	Computed based on a hypothetical investment of $100 in common stock on July 1, 2024.

(4)	The following table summarizes the applicable deductions and additions for the PEO in the calculation of Compensation Actually Paid to the PEO.

(5)	The following table summarizes the applicable deductions and additions for the NEO in the calculation of Compensation Actually Paid to the NEO.

Year	Total Compensation per Summary Compensation Table Less Stock Awards		Year End Fair Value of Stock Awards Granted and Unvested During Applicable Year			Change in Fair Value as of Year End of Any Prior Awards that Remain Unvested as of Year End		Awards Granted and Vested in the Same Year, at Fair Value as of the Vesting Date	Change in Fair Value as of Year End of Any Prior Awards that Vested During Applicable Year		Compensation Actually Paid to PEO
2026	$	560,500		$	-		$	-	$	-		$	-	$	560,500
2025	$	560,032		$	-		$	-	$	-		$	-	$	560,032

Year

Total Compensation per Summary Compensation Table Less Stock Awards

Year End Fair Value of Stock Awards Granted and Unvested During Applicable Year

Change in Fair Value as of Year End of Any Prior Awards that Remain Unvested as of Year End

Awards Granted and Vested in the Same Year, at Fair Value as of the Vesting Date

Change in Fair Value as of Year End of Any Prior Awards that Vested During Applicable Year

Less: Prior Fiscal Year-End

Fair Value of Forfeited Awards

Compensation Actually Paid to NEO

2026

131,881

6,112

(1,061

)

(192

)

(33,412

)

103,328

2025

128,080

46,404.87

174,485

EQUITY COMPENSATION PLAN INFORMATION

The 2018 Plan provides for the grant of stock\noptions (incentive and non-qualified), stock awards (including RSUs and deferred stock units), stock appreciation rights and cash awards.\nAs of September 16, 2026, we have available for future issuance an aggregate 1,042,187 shares under the 2018 Plan, plus an annual\nincrease on the first day of each calendar year remaining of the 10-year term of the 2018 Plan, equal to the lesser of (i) five percent\n(5%) of the shares of our common stock outstanding on the final day of the immediately preceding calendar year, or (ii) a lesser number\nof shares as determined by our Compensation Committee. To the extent that shares of common stock subject to an outstanding award granted\nunder the 2018 Plan are not issued or delivered by reason of the expiration, termination, cancellation or forfeiture of such award (excluding\nshares of common stock subject to an option cancelled upon settlement in shares of common stock of a related tandem share appreciation\nright or shares of common stock subject to a tandem share appreciation right cancelled upon exercise of a related option) or by reason\nof the settlement of an award in cash, then those shares of common stock will again be available under the 2018 Plan, other than for grants\nof incentive stock options. In addition, any shares covered by an award that have been surrendered in connection with the payment of the\naward exercise or purchase price or in satisfaction of tax withholding obligations incident to the grant, exercise, vesting or settlement\nof an award will be deemed not to have been issued for purposes of determining the maximum number of shares of common stock which may\nbe issued pursuant to all awards under the 2018 Plan.

The following table sets forth the number of shares\nof common stock subject to outstanding options, RSUs, deferred stock units, warrants and other convertible securities into share rights,\nthe weighted-average exercise price of outstanding options, and the number of shares remaining available for future award grants as of\nJune 30, 2026.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

Plan Category

(A)
Number of securities to be issued upon exercise of outstanding restricted stock units, options, warrants and rights (1)

(B)
Weighted-average exercise price of outstanding options, warrants and rights

(C)
Number of securities remaining for future issuance under equity compensation plans (excluding securities reflected in Column (A)) (2)

Equity compensation plans approved by stockholders

1,072,431

7.61

1,042,187

Equity compensation plans not approved by stockholders

N/A

\n\n

(1)

Includes 1,072,431 shares subject\nto outstanding stock options, RSUs and deferred stock units under the 2018 Equity Incentive Plan. The weighted average exercise price\nin column (B) does not take RSUs or deferred stock units into account.

\n\n

(2)

Based on 1,042,187 shares of common\nstock reserved for issuance under the 2018 Equity Incentive Plan, plus annual increases on the first day of each calendar year during\nthe initial ten-year term of the Plan, less shares previously issued and outstanding.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS\nAND MANAGEMENT

The following table sets forth certain information\nregarding beneficial ownership of shares of our common stock as of September 16, 2026, based on 6,549,851 shares issued and outstanding\nby (i) each person known to beneficially own more than 5% of our outstanding common stock, (ii) each of our directors and director nominees,\n(iii) our named executive officers and (iv) all directors and executive officers as a group. Shares are beneficially owned when an individual\nhas voting and/or investment power over the shares or could obtain voting and/or investment power over the shares within 60 days of September\n16, 2026. Except as otherwise indicated, the persons named in the table have sole voting and investment power with respect to all shares\nbeneficially owned, subject to community property laws, where applicable. Unless otherwise indicated, the address of each beneficial owner\nlisted below is c/o Amesite Inc., 607 Shelby Street, Suite 700 PMB 214, Detroit, Michigan 48226.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

Name of Beneficial Owner and Title of Named Executive Officers and Directors	Shares of Common Stock Beneficially Owned		Percentage
Ann Marie Sastry, Ph.D., President, Chief Executive Officer, and Chairman of the Board ⁽¹⁾		1,093,397		16.7	%
Sarah Berman, Principal Financial and Accounting Officer		677		*
Brandon Owens, Former Vice President of Sales		3,750		*
J. Michael Losh, Director ⁽²⁾		172,299		2.6	%
Gilbert S. Omenn, M.D., Ph.D., Director ⁽³⁾		165,041		2.5	%
Barbie Brewer, Director ⁽⁴⁾		165,909		2.5	%
George Parmer, Director ⁽⁵⁾		571,221		8.7	%

All Executive Officers and Directors as a Group (7 persons) ⁽⁶⁾		2,172,294		33.2	%

Beneficial Owner Greater than 5% Stockholders
Ann Marie Sastry, Ph.D., President, Chief Executive Officer, and Chairman of the Board ⁽¹⁾		1,093,397		16.7	%
George Parmer, Director ⁽⁵⁾		571,221		8.7	%

\n\n\n\n

*	Less than 1%.

\n\n

(1)

Includes (i) 1,049,647 shares\nof common stock held by Dr. Sastry and (ii) 43,750 shares of common stock underlying options that are presently exercisable or exercisable\nwithin 60 days of September 16, 2026 held by Dr. Sastry. The shares of common stock reported excludes 174,216 shares of common stock\nunderlying Series A-1 Warrants and 174,216 shares of common stock underlying Series A-2 Warrants.

\n\n

(2)

Includes (i) 138,200 shares of\ncommon stock held by Mr. Losh and (ii) 34,099 shares of common stock underlying options that are presently exercisable or exercisable\nwithin 60 days of September 16, 2026, but excludes 101,265 shares of common stock underlying deferred stock units that may be issued\nin the Company’s discretion upon completion of service as a member of the board of directors, or if earlier, upon a change in control.

\n\n

(3)

Includes (i) 143,699 shares of\ncommon stock held by Dr. Omenn and (ii) 21,342 shares of common stock underlying options that are presently exercisable or exercisable\nwithin 60 days of September 16, 2026, but excludes 83,806 shares of common stock underlying\ndeferred stock units that may be issued in the Company’s discretion upon completion of service as a member of the board of directors,\nor if earlier, upon a change in control.

\n\n

(4)

Includes (i) 135,977 shares of\ncommon stock held by Ms. Brewer and (ii) 29,932 shares of common stock underlying options that are presently exercisable or exercisable\nwithin 60 days of September 16, 2026, but excludes 40,754 shares of common stock underlying\ndeferred stock units that may be issued in the Company’s discretion upon completion of service as a member of the board of directors,\nor if earlier, upon a change in control.

\n\n

(5)

Includes (i) 566,962 shares of\ncommon stock held by Mr. Parmer, (ii) 4,259 shares of common stock underlying options that are presently exercisable or exercisable within\n60 days of September 16, 2026, but excludes 76,910 shares of common stock underlying deferred stock units that may be issued in the Company’s\ndiscretion upon completion of service as a member of the board of directors, or if earlier, upon a change in control. The shares of common\nstock reported excludes 243,902 shares of common stock underlying Series A-1 Warrants and 243,902 shares of common stock underlying Series\nA-2 Warrants.

\n\n

(6)

Includes 137,809 shares of common\nstock underlying options that are either presently exercisable or exercisable within 60 days of September 16, 2026 held by all directors\nand officers as a group.

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

The following is a description\nof transactions since July 1, 2023 to which the Company party, in which the amount involved exceeds the lesser of $120,000 or one percent\nof the average of the Company’s total assets at year-end for the last two completed fiscal years, and in which any of our respective\ndirectors, director nominees, executive officers or beneficial owners of more than 5% of our capital stock, or an affiliate or immediate\nfamily member thereof, had or will have a direct or indirect material interest.

Indemnification Agreements and Directors’\nand Officers’ Liability Insurance

We plan to enter into indemnification\nagreements with each of our directors and executive officers. These agreements, among other things, will require us to indemnify each\ndirector and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys’\nfees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any\naction or proceeding by or in right of us, arising out of the person’s services as a director or executive officer.

April 2026 Private Placement

On April 27, 2026, in connection\nwith the Company’s registered direct offering and concurrent private placement of shares of common stock and warrants, the Company\nentered into purchase agreements with certain of its officers and directors, including Dr. Ann Marie Sastry, Ph.D., the Company’s\nChairman and Chief Executive Officer, and George Parmer, a member of the Company’s board of directors. Pursuant to these agreements,\nthe Company agreed to issue and sell to such officers and directors in a private placement transaction (the “Insider-Led Private\nPlacement”) (i) an aggregate of 418,118 shares of common stock, (ii) Series A-1 Warrants to purchase an aggregate of 418,118 shares\nof common stock and (iii) Series A-2 Warrants to purchase an aggregate of 418,118 shares of common stock, at a combined purchase price\nof $1.435 per share of common stock and accompanying Common Warrants. The aggregate gross proceeds from the Insider-Led Private Placement\nwere approximately $600,000.

Related Person Transaction Policy

We have not had a formal policy\nregarding approval of transactions with related parties. We expect to adopt a related person transaction policy that will set forth procedures\nfor the identification, review, consideration and approval or ratification of related person transactions. For purposes of the policy\nonly, a related person transaction will be a transaction, arrangement or relationship, or any series of similar transactions, arrangements\nor relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds the lesser\nof $120,000 or one percent of our total assets at year-end for our last two completed fiscal years. Transactions involving compensation\nfor services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director\nor beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity\nowned or controlled by such persons.

Under the policy we plan to\nadopt, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction\nwhen originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation,\nour management must present information regarding the related person transaction to our audit committee, or, if audit committee approval\nwould be inappropriate, to another independent body of our board of directors, for review, consideration and approval or ratification.\nThe presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related\npersons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or\nfrom, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that\nwe deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to\nidentify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our code\nof business conduct and ethics, our employees and directors will have an affirmative responsibility to disclose any transaction or relationship\nthat reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee,\nor other independent body of our board of directors, will take into account the relevant available facts and circumstances including,\nbut not limited to:

\n\n\n\n\n\n\n\n\n\n\n\n\n

	●	the risks, costs and benefits to us;

	●	the impact on a director’s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated;

\n\n\n\n\n\n\n\n\n\n\n\n\n

	●	the availability of other sources for comparable services or products;

	●	the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.

The policy will require that,\nin determining whether to approve, ratify or reject a related person transaction, our audit committee, or other independent body of our\nboard of directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best\ninterests and those of our stockholders, as our audit committee, or other independent body of our board of directors, determines in the\ngood faith exercise of its discretion.

OTHER MATTERS

The board of directors knows\nof no other business, which will be presented to the Annual Meeting. If any other business is properly brought before the Annual Meeting,\nproxies in the enclosed form will be voted in accordance with the judgment of the persons voting the proxies.

We will bear the cost of soliciting\nproxies in the accompanying form. In addition to the use of the mails, proxies may also be solicited by our directors, officers or other\nemployees, personally or by telephone, facsimile or email, none of whom will be compensated separately for these solicitation activities.

If you do not plan to attend\nthe Annual Meeting, in order that your shares may be represented and in order to assure the required quorum, please sign, date and return\nyour proxy promptly. In the event you are able to attend the Annual Meeting virtually, at your request, we will cancel your previously\nsubmitted proxy.

STOCKHOLDER PROPOSALS

Stockholders who intend to\npresent a proposal for inclusion in the proxy statement for the annual meeting of stockholders that follows the Annual Meeting to be held\non December 10, 2026, must follow the procedures outlined in Rule 14a-8 under the Exchange Act. A proposal that a stockholder would like\nincluded in our proxy statement for the such annual meeting must satisfy all applicable requirements of Rule 14a-8 and must be received\nat our principal executive offices at Amesite Inc., Attn: Secretary, 607 Shelby Street, Suite 700 PMB 214, Detroit, Michigan 48226, no\nlater than June 16, 2027.

Stockholders who intend to\npresent a proposal (other than pursuant to Rule 14a-8) at the annual meeting of stockholders that follows the Annual Meeting to be held\non December 10, 2026, and who wish to have such proposals included in the proxy statement for such meeting must submit such proposals\nin writing by notice delivered or mailed by first-class United States mail, postage prepaid, to the Secretary at Amesite Inc., Attn: Secretary,\n607 Shelby Street, Suite 700 PMB 214, Detroit, Michigan 48226, and such proposals must be received no earlier than August 12, 2027 and\nno later than September 11, 2027.

STOCKHOLDER RECOMMENDATIONS FOR NOMINATIONS\nTO THE BOARD

The Corporate Governance and\nNominating Committee will consider nominees recommended by stockholders. Pursuant to our Bylaws, stockholders who wish to recommend a\ncandidate for consideration at the annual meeting of stockholders that follows the Annual Meeting to be held on December 10, 2026, may\ndo so by delivering a written recommendation to our Secretary at Amesite Inc., Attn: Secretary, 607 Shelby Street, Suite 700 PMB 214,\nDetroit, Michigan 48226. The recommendation must include the information required pursuant to the Company’s Bylaws, including all\nof the information that would be required to be disclosed pursuant to Item 404 of Regulation S-K under the Exchange Act, the candidate’s\nwritten consent to be considered for nomination and to serve if nominated and elected and addresses and telephone numbers for contacting\nthe stockholder and the candidate for more information.

A stockholder who wishes to\nnominate an individual as a candidate for election, rather than recommend the individual to the Corporate Governance and Nominating Committee\nas a nominee, must comply with the notice procedures set forth in our Bylaws. Stockholders who wish to nominate a director must additionally\nbe a stockholder of record on both the date of the giving of notice by such stockholder and the date of the relevant annual meeting. Such\nproposals must additionally meet the requirements set forth in the rules and regulations of the SEC, as well as the informational, notice\nand other requirements related to proposals set forth in Section 2.5 of our Bylaws, in order to be eligible for inclusion in our proxy\nstatement for such annual meeting. If you intend to nominate one or more directors, you must give timely notice thereof in writing to\nthe Secretary at the address set forth above. Our Secretary must receive the notice not less than 90 days and not more than 120 days before\nthe one-year anniversary of the immediately preceding annual general meeting of stockholders. This means that for the annual meeting of\nstockholders that follows the Annual Meeting to be held on December 10, 2026, our secretary must receive the notice no earlier than August\n12, 2027 and no later than September 11, 2027.

In addition to satisfying\nthe requirements set forth in our Bylaws, including the notice deadlines set forth above and therein, to comply with the requirements\nset forth in Rule 14a-19 of the Exchange Act (the universal proxy rules), stockholders who intend to solicit proxies in support of director\nnominees other than the Board’s nominees must also provide written notice to our Secretary that sets forth all the information required\nby Rule 14a-19(b) of the Exchange Act. Such notice must be postmarked or transmitted electronically to the Company at our principal executive\noffices at Amesite Inc., Attn: Secretary, 607 Shelby Street, Suite 700 PMB 214, Detroit, Michigan 48226, no later than October 11, 2027.\nHowever, if the date of the annual meeting of stockholders that follows the Annual Meeting to be held on December 10, 2026 is changed\nby more than 30 calendar days from December 10, 2027, then written notice must be provided by the later of 60 calendar days prior to the\ndate of such annual meeting or the 10th calendar day following the day on which public announcement of the date of the such annual meeting\nis first made by us.

HOUSEHOLDING

The SEC has adopted rules\nthat permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and other Annual Meeting\nmaterials with respect to two or more stockholders sharing the same address by delivering a single copy of the proxy statement or other\nAnnual Meeting materials addressed to those stockholders. This process, which is commonly referred to as householding, potentially provides\nextra convenience for stockholders and cost savings for companies. Stockholders who participate in householding will continue to be able\nto access and receive separate proxy cards.

If you share an address with\nanother stockholder and have received multiple copies of our proxy materials, you may write or call us at the address or phone number\nbelow to request delivery of a single copy of the notice and, if applicable, other proxy materials in the future. We undertake to deliver\npromptly upon written or oral request a separate copy of the proxy materials, as requested, to a stockholder at a shared address to which\na single copy of the proxy materials was delivered. If you hold stock as a record stockholder and prefer to receive separate copies of\nour proxy materials either now or in the future, please contact us at 607 Shelby Street, Suite 700 PMB 214, Detroit, Michigan 48226, Attn:\nSecretary, or by phone at (734) 876-8130. If your stock is held through a brokerage firm or bank and you prefer to receive separate copies\nof our proxy materials either now or in the future, please contact your brokerage firm or bank.

ANNUAL REPORT

Additional copies of our Annual\nReport on Form 10-K for the fiscal year ended June 30, 2026 may be obtained without charge by writing to the Company’s Secretary,\n607 Shelby Street, Suite 700 PMB 214, Detroit, Michigan 48226.

Our audited financial statements\nfor the fiscal year ended June 30, 2026 and certain other related financial and business information are contained in our 2026 Annual\nReport to Stockholders, which is being made available to our stockholders along with this proxy statement, but which is not deemed a part\nof the proxy soliciting material.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

	BY ORDER OF THE BOARD OF DIRECTORS

	/s/ Ann Marie Sastry, Ph.D.
	Ann Marie Sastry, Ph.D.
October 14, 2026	Chairman of the Board of Directors

APPENDIX A

CERTIFICATE OF AMENDMENT

to the

CERTIFICATE OF INCORPORATION

AMESITE INC.

AMESITE INC., a corporation\norganized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as\nfollows:

FIRST: The name of the Corporation\nis Amesite Inc. The Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on September 18, 2020,\nas amended on February 17, 2023 (the “Certificate of Incorporation”).

SECOND: The Corporation’s\nCertificate of Incorporation, as amended, is further amended by deleting Section C of Article IV in its entirety and restating it as follows:

C. Reverse Stock Split.\nUpon the filing and effectiveness (the “Effective Time”) of this Certificate of Amendment pursuant to the Section 242 of the\nGeneral Corporation Law of the State of Delaware, each [__] ([__]) shares of the Corporation’s common stock, issued and outstanding immediately\nprior to the Effective Time (the “Old Common Stock”) shall automatically without further action on the part of the Corporation\nor any holder of Old Common Stock, be reclassified, combined, converted and changed into [__] ([__]) fully paid and nonassessable shares\nof common stock, par value of $0.0001 per share (the “New Common Stock”), subject to the treatment of fractional share interests\nas described below (the “reverse stock split”). The conversion of the Old Common Stock into New Common Stock will be deemed\nto occur at the Effective Time. From and after the Effective Time, certificates representing the Old Common Stock shall represent the\nnumber of shares of New Common Stock into which such Old Common Stock shall have been converted pursuant to this Certificate of Amendment.\nHolders who otherwise would be entitled to receive fractional share interests of New Common Stock upon the effectiveness of the reverse\nstock split shall be entitled to receive a whole share of New Common Stock in lieu of any fractional share created as a result of such\nreverse stock split.

THIRD: The stockholders of the Corporation have\nduly approved the foregoing amendment in accordance with the provisions of Section 242 of the General Corporation Law of the State of\nDelaware.

IN WITNESS WHEREOF,\nthe Corporation has caused this Certificate of Amendment to be duly adopted and executed in its corporate name and on its behalf by its\nduly authorized officer as of the ___ day of __________, 2026.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

AMESITE INC.

By:
Name:	Ann Marie Sastry, Ph.D.

A-1

AMESITE INC.

PROXY FOR ANNUAL MEETING TO BE HELD ON DECEMBER\n10, 2026
\nTHIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

The undersigned hereby appoints Ann Marie Sastry,\nPh.D. as proxy with full power of substitution, to represent and to vote all the shares of common stock of Amesite Inc. (the “Company”),\nwhich the undersigned would be entitled to vote, at the Company’s Annual Meeting of Stockholders to be held December 10, 2026 and\nat any adjournments thereof, subject to the directions indicated on this Proxy Card.

In their discretion, the proxies are authorized\nto vote upon any other matter that may properly come before the meeting or any adjournments or postponements thereof.

THIS PROXY WILL BE VOTED IN ACCORDANCE WITH THE\nSPECIFICATIONS MADE, BUT IF NO CHOICES ARE INDICATED, THIS PROXY WILL BE VOTED BY THE PROXY HOLDERS FOR THE ELECTION OF ALL NOMINEES AND\nFOR THE PROPOSALS LISTED ON THE REVERSE SIDE AND IN THEIR DISCRETION ON ANY OTHER MATTERS THAT ARE PROPERLY PRESENTED AT THE MEETING OR\nANY ADJOURNMENTS OR POSTPONEMENTS THEREOF.

The Annual Meeting of Stockholders of Amesite\nInc. will be held virtually on December 10, 2026 at 10:00 a.m. Eastern Time at www.virtualshareholdermeeting.com/AMST2027.

THIS IS YOUR PROXY
\nYOUR VOTE IS IMPORTANT!

Dear Stockholder:

We cordially invite you to attend the Annual Meeting of Stockholders\nof Amesite Inc. to be held virtually at www.virtualshareholdermeeting.com/AMST2027, on December 10, 2026 beginning at 10:00 a.m. Eastern\nTime.

Please read the proxy statement which describes\nthe proposals and presents other important information, and complete, sign and return your proxy promptly in the enclosed envelope.

Important Notice Regarding the Availability\nof Proxy Materials for the Annual Meeting:

The Notice and Proxy Statement and Form 10-K are\navailable at www.proxyvote.com.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR\nPROPOSALS 1, 2, 3, 4 & 5, AND “1 YEAR” ON PROPOSAL 6.

1. Election of two Class III Director Nominees	\n FOR \n ALL	\n WITHHOLD \n ALL	FOR ALL EXCEPT
01 - Gilbert S. Omenn, M.D., Ph.D. \n02 - George Parmer	☐	☐	☐

2. Proposal to ratify Novogradac & Company LLP as the Company’s independent registered public accountants for the fiscal year ending June 30, 2027.	\n FOR \n ☐	\n AGAINST \n ☐	\n ABSTAIN \n ☐

3. Proposal to approve an amendment to the Company’s Certificate of Incorporation, at the discretion of the Board, to effect a reverse stock split with respect to the Company’s issued and outstanding common stock, at a ratio of 1-for-2 to 1-for-250, with the ratio to be determined at the discretion of the Board, and to effect the reverse stock split within one year after the date of approval.	\n FOR \n ☐	\n AGAINST \n ☐	\n ABSTAIN \n ☐

4. Proposal to approve, for purposes of Nasdaq Listing Rule 5635(d), the issuance of securities in one or more non-public offerings where such issuance exceeds 19.99% of outstanding shares at less than the Nasdaq minimum price, within one year after the date of approval, subject to certain limitations, for aggregate proceeds of up to $25 million.	\n FOR \n ☐	\n AGAINST \n ☐	\n ABSTAIN \n ☐

5. Proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers.	\n FOR \n ☐	\n AGAINST \n ☐	\n ABSTAIN \n ☐

6. Proposal to indicate, on an advisory basis, the preferred frequency of holding future advisory votes on the compensation of the Company’s named executive officers.	\n 1 YEAR \n ☐	\n 2 YEARS \n ☐	\n 3 YEARS \n ☐

	\n ABSTAIN \n ☐

NOTE: Such other business as may properly\ncome before the meeting or any adjournment thereof will be voted on by the proxy holders in their discretion.

Please sign exactly as your name(s) appear(s)\nhereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each\nsign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized\nofficer.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

Dated:________________

Signature

Signature
(Joint Owners)

Name (printed)

VOTING INSTRUCTIONS

You may vote your proxy in the following ways:

\n\n\n\n

1.	VIA INTERNET:

Before The Meeting - Go to www.proxyvote.com or scan\nthe QR Barcode above

Use the Internet to transmit your voting instructions\nand for electronic delivery of information up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your\nproxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting\ninstruction form.

During The Meeting - Go to www.virtualshareholdermeeting.com/AMST2027\n

You may attend the meeting via the Internet and\nvote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions.

\n\n\n\n

2.	VIA PHONE: 1-800-690-6903

Use any touch-tone telephone to transmit your\nvoting instructions up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when\nyou call and then follow the instructions.

\n\n\n\n

VIA MAIL:

Mark, sign and date your proxy card and return\nit in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

","original","zhKind","translation","complete",false,"AMST","公司与财报","政策与监管","其他","IPO","退市","停复牌","aihot","/items/fd8r8afpu4faiu3gixovhmyuw","https://www.sec.gov/Archives/edgar/data/1807166/000121390026109433/0001213900-26-109433-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792281600&sig=7e2c0b2887bde829","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792281600&sig=4a4e737d69fc85ba 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792281600&sig=f06d97a3bb025478 96w","changelogVersion","2026-10-01T08:00"]